<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006456" GROUP_ID="MOVEMENT" ID="719906102601305046" MERGED_FROM="" MODIFIED="2009-05-08 16:44:53 +0200" MODIFIED_BY="Ema Roque" NOTES="&lt;p&gt;Exported from Review Manager 4.2.10&lt;br&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.9&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-04-26 15:25:56 +0100" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.18" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2009-04-10 19:52:50 +0100" MODIFIED_BY="[Empty name]">
<TITLE>Therapeutic interventions for symptomatic treatment in Huntington's disease</TITLE>
<CONTACT>
<PERSON ID="9CC9BE5C82E26AA2012C734C85CBB923" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tiago</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Mestre</LAST_NAME>
<SUFFIX/>
<POSITION>Neurology Resident</POSITION>
<EMAIL_1>tmestre@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neurological Clinical Research Unit</DEPARTMENT>
<ORGANISATION>Institute of Molecular Medicine</ORGANISATION>
<ADDRESS_1>Hospital de Santa Maria</ADDRESS_1>
<ADDRESS_2>Av. Prof. Egas Moniz</ADDRESS_2>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+351 917532125</PHONE_1>
<PHONE_2/>
<FAX_1>+ 351 217802129</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2009-04-10 19:52:50 +0100" MODIFIED_BY="[Empty name]">
<PERSON ID="9CC9BE5C82E26AA2012C734C85CBB923" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Tiago</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Mestre</LAST_NAME>
<SUFFIX/>
<POSITION>Neurology Resident</POSITION>
<EMAIL_1>tmestre@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neurological Clinical Research Unit</DEPARTMENT>
<ORGANISATION>Institute of Molecular Medicine</ORGANISATION>
<ADDRESS_1>Hospital de Santa Maria</ADDRESS_1>
<ADDRESS_2>Av. Prof. Egas Moniz</ADDRESS_2>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+351 917532125</PHONE_1>
<PHONE_2/>
<FAX_1>+ 351 217802129</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6005" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Joaquim</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Ferreira</LAST_NAME>
<SUFFIX/>
<POSITION>Co-ordinator, Cochrane Movement Disorders Group</POSITION>
<EMAIL_1>movementdisord@fm.ul.pt</EMAIL_1>
<EMAIL_2/>
<URL>http://www.fm.ul.pt/Movement-disorders</URL>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Hospital de Santa Maria</ADDRESS_1>
<ADDRESS_2>Av. Prof. Egas Moniz</ADDRESS_2>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+ 351 21 797 3453</PHONE_1>
<PHONE_2/>
<FAX_1>+ 351 21 780 2129</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="14797" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Miguel</FIRST_NAME>
<MIDDLE_INITIALS>M</MIDDLE_INITIALS>
<LAST_NAME>Coelho</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>movementdisord@mail.telepac.pt</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Av. Prof. Egas Moniz</ADDRESS_1>
<ADDRESS_2/>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+ 351 21 797 34 53</PHONE_1>
<PHONE_2/>
<FAX_1>+ 351 21 781 96 88</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="87E9223582E26AA20104C58E72B84E4C" MODIFIED="2009-04-10 19:52:50 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Mário</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rosa</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1/>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Neurological Clinical Research Unit</DEPARTMENT>
<ORGANISATION>Institute of Molecular Medicine</ORGANISATION>
<ADDRESS_1>Centro de Estudos Egas Moniz</ADDRESS_1>
<ADDRESS_2>Faculdade de Medicina de Lisboa, Av. Prof. Egas Moniz</ADDRESS_2>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+ 351 21 7930629</PHONE_1>
<PHONE_2/>
<FAX_1>+ 351 21 7957474</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="6111" MODIFIED="2009-04-10 19:52:50 +0100" MODIFIED_BY="[Empty name]" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Cristina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Sampaio</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>movementdisord@fm.ul.pt</EMAIL_1>
<EMAIL_2>movementdisord@mail.telepac.pt</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Laboratório de Farmacologia Clínica e Terapêutica</DEPARTMENT>
<ORGANISATION>Faculdade de Medicina de Lisboa</ORGANISATION>
<ADDRESS_1>Hospital de Santa Maria</ADDRESS_1>
<ADDRESS_2>Av. Prof. Egas Moniz</ADDRESS_2>
<CITY>Lisboa</CITY>
<ZIP>1649-028</ZIP>
<REGION/>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<PHONE_1>+ 351 21 797 34 53</PHONE_1>
<PHONE_2/>
<FAX_1>+ 351 21 780 2129</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2009-01-19 04:14:32 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Minor update: 11/08/08&lt;/p&gt;" NOTES_MODIFIED="2009-01-19 04:14:32 +0000" NOTES_MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="23" MONTH="12" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="23" MONTH="12" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="15" MONTH="1" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2007"/>
<REVIEW_PUBLISHED ISSUE="" YEAR=""/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2007"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="11" MONTH="8" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="23" MONTH="12" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Movement Disorders Cochrane Review Group</NAME>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Neurological Clinical Research Unit, Institute of Molecular Medicine</NAME>
<COUNTRY CODE="PT">Portugal</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-04-26 14:06:49 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2009-04-26 13:32:14 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-08-20 12:47:33 +0100" MODIFIED_BY="[Empty name]">Interventions to control symptoms in Huntington's disease</TITLE>
<SUMMARY_BODY MODIFIED="2009-04-26 13:32:14 +0100" MODIFIED_BY="[Empty name]">
<P>Huntington's disease (HD) is an autosomal dominant neurodegenerative disease. No curative therapy is currently available. We proposed to assess the effectiveness of interventions aimed at controlling the symptoms of HD and to analyse the methodological quality of the corresponding clinical trials. 22 trials were identified. The review of these trials comprising 1254 HD patients revealed that no intervention produced a robust conclusive symptomatic effect. Nevertheless, tetrabenazine was the drug for which better data exists supporting a beneficial effect in the treatment of chorea. There were no available data for the specific treatment of other clinical relevant problems associated with HD such as depression, irritability, apathy, cognitive impairment or psychosis.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-04-26 13:31:14 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2009-04-26 13:27:19 +0100" MODIFIED_BY="[Empty name]">
<P>Huntington's disease (HD) is an orphan autosomal dominant neurodegenerative disorder caused by the amplification of a nucleic acids triplet repeat. It is characterised by core symptoms of chorea, progressive dementia and psychiatric manifestations such as depression, irritability, apathy and psychosis. In current clinical practice, drugs exist that seem to improve symptoms for HD patients. However, their effectiveness has not been fully measured.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the effectiveness of the available interventions for the symptomatic treatment of HD.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-01-19 03:47:33 +0000" MODIFIED_BY="[Empty name]">
<P>The search strategy developed for the Movement Disorders Group was undertaken. Cochrane Controlled Trials Register, Medline, EMBASE and Clinical Trials Database of the United States National Institute of Health were thoroughly searched up until December 2007.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-04-26 13:29:31 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised, double-blinded, placebo-controlled clinical trials conducted on any symptomatic therapy used for HD with at least ten participants were included. Participants should have HD clinical features and a confirmatory genetic diagnosis or a compatible family history. All disease variants and ages of disease onset were included. Cross-over studies were included. All pharmacological and non-pharmacological interventions aimed at the control of signs and symptoms associated with HD were to be selected.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-01-19 03:48:24 +0000" MODIFIED_BY="[Empty name]">
<P>Two reviewers independently assessed the identified trials for eligibility. In the selected trials, the assessment of their methodological quality was done according to the Cochrane Collaboration handbook, and eligible data were registered onto standardised forms. If possible, an intention-to-treat analysis was conducted. When data were not available in the original publication, the principal investigator of the trial was contacted. A meta-analysis was conducted when possible and otherwise the descriptive summary of the results was provided. The software Revman 5.0.15 was used for statistical analysis.<BR/>
</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-04-26 13:31:14 +0100" MODIFIED_BY="[Empty name]">
<P>22 trials (1254 participants) were included. Nine trials had a cross-over design and 13 were conducted in parallel. Study duration ranged from 2 to 80 weeks. Various pharmacological interventions were studied, mostly, they were anti-dopaminergic drugs (n = 5), glutamate receptor antagonists (n = 5) and energy metabolites (n = 5). Only tetrabenazine showed a clear efficacy for the control of chorea. The remaining pharmacological interventions revealed no clear effectiveness.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-01-19 03:49:06 +0000" MODIFIED_BY="[Empty name]">
<P>No intervention proved to have a consistent symptomatic control in HD. Tetrabenazine is the anti-choreic drug with the best quality data available. Other symptomatic areas should be explored by well-designed randomised placebo-controlled studies.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-04-26 14:06:49 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2009-04-26 12:25:51 +0100" MODIFIED_BY="[Empty name]">
<P>HD, also known as Huntington's chorea, was first described by the eponymous North American physician George Huntington in 1872 (<LINK REF="REF-Lanska-1995" TYPE="REFERENCE">Lanska 1995</LINK>). It is characterised by choreiform movements, progressive dementia and psychiatric manifestations (depression, psychosis, apathy, irritability). Choreiform movements consist of involuntary, rapid, irregular, jerky motor actions, including facial twitching or writhing, and twitching of distal extremities, but also may manifest itself in more generalised forms that can impair gait (<LINK REF="REF-Ropper-2005" TYPE="REFERENCE">Ropper 2005</LINK>). HD is an autosomal dominant inherited disease, meaning that the child of an affected patient has a 50 % chance to develop the disease. The causative gene is located in chromosome 4 and encodes a protein known as huntingtin (<LINK REF="REF-TH-s-DCR-Group-1993" TYPE="REFERENCE">TH s DCR Group 1993</LINK>). Huntingtin gradually accumulates within brain cells, causing damage and cell death in certain brain areas, namely the basal ganglia and neocortex. The rate of accumulation of huntingtin is associated with the number of repeats of a specific sequence of three nucleic acids (CAG). A greater number of repeats is associated with an earlier disease onset (<LINK REF="REF-Kieburtz-1994" TYPE="REFERENCE">Kieburtz 1994</LINK>). HD is encountered throughout the world and in all ethnic groups. The global prevalence of HD is estimated to be 4-5 per one million people. In western countries it is estimated to be 8-10 per 100.000 people. There is no gender predominance. HD usually begins between the ages of 30 to 50 and determines death 15 to 20 years after the onset of neurological manifestations (<LINK REF="REF-Ropper-2005" TYPE="REFERENCE">Ropper 2005</LINK>). An early onset variant exists (Juvenile HD or Westphal variant) and typically begins in adolescence. In contrast with the adult form, it manifests with slowness of movement (bradykinesia) and increased muscular tone (rigidity type). It presents a more severe course with an average survival of 5 to 10 years (<LINK REF="REF-Ropper-2005" TYPE="REFERENCE">Ropper 2005</LINK>) after the onset of disease.</P>
<P>In current clinical practice, there is a broad spectrum of therapeutic interventions proposed for the symptomatic treatment of HD (<LINK REF="REF-Bonneli-RM-2005" TYPE="REFERENCE">Bonneli RM 2005</LINK>). However, the rational for its use comes essentially from clinical practice and by the extrapolation of results obtained in interventional studies performed in other neurological diseases. This scenario calls for a critical appraisal of the efficacy and safety of all proposed symptomatic therapeutic interventions conducted specifically for the treatment of HD.</P>
<P>Preliminary examination of the literature also suggests a wide variation in the design, outcomes and quality of studies evaluating therapeutic interventions, which further underlines the need for a systematic review of the most reliable evidence. The present review critically analyses the best available clinical data about therapeutic interventions applied to the control the symptoms of HD.</P>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-01-12 19:02:57 +0000" MODIFIED_BY="[Empty name]">
<P>Evaluate the effectiveness of therapeutic interventions aimed at controlling the symptoms of HD.</P>
</OBJECTIVES>
<METHODS MODIFIED="2009-04-26 14:06:49 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2009-04-26 14:06:49 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2009-01-19 03:51:31 +0000" MODIFIED_BY="[Empty name]">
<P>All randomised, controlled, clinical trials of therapeutics investigated for the symptomatic control in HD. Trials with less than ten patients were excluded as well as those in which allocation was not adequately concealed.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-04-26 12:22:31 +0100" MODIFIED_BY="[Empty name]">
<P>Participants with HD clinical features and a confirmatory genetic diagnosis or a compatible family history. All disease variants and all ages of disease onset were included. All possible concomitant therapies were accepted.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-04-26 13:34:55 +0100" MODIFIED_BY="[Empty name]">
<P>All pharmacological and non-pharmacological interventions aimed at controlling signs and symptoms associated with HD were selected. For clinical problems in which no placebo-controlled trials could be found, we allowed the inclusion of randomised comparisons of pharmacological interventions for which a 'standard' treatment is consensually accepted by the medical community to have a degree of efficacy for the treatment of a specific problem (for example, classical neuroleptics for the control of chorea). 
<B>
<BR/>
</B>

</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-04-26 14:06:49 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-04-26 13:35:35 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Effect on depression (measured by patient-rated scales such as the Beck Depression Inventory or by clinician-rated scales, such as the Hamilton Rating Scale for Depression).</LI>
<LI>Effect on cognition measured by performance on objective tests of cognitive function [for example, memory, attention, name-finding, speed of processing or global measures such as Mini Mental State Examination (MMSE) or Alzheimer´s Disease Assessment Scale - cognitive subscale(ADAS-cog)].</LI>
<LI>Effect on chorea/dyskinesias measured by quantitative scales like Abnormal Involuntary Movement Scale (AIMS) or Unified Huntington's Disease Rating Scale (UHDRS) (<LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</LI>
<LI>Effect on behavioural disturbance and psychosis.</LI>
<LI>Effect on functional performance measured by functional scales like the Total Functional Capacity (TFC) subscale of the UHDRS( <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>).</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-04-26 14:06:49 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Physician and/or patients´ global clinical impression.</LI>
<LI>Quality of life measured by generally accepted scales (e.g. SF-36).</LI>
<LI>Change in burden for patient caregiver (e.g. caregiver questionnaires).</LI>
<LI>Death.</LI>
<LI>Tolerability of treatment measured by withdrawal from trials.</LI>
<LI>Safety measured by the incidence and nature of adverse effects, the occurrence of adverse effects leading to withdrawal and serious adverse effects defined as any adverse event that is life-threatening or results in death, hospitalisation or prolonged incapacity/disability.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-04-26 12:32:47 +0100" MODIFIED_BY="[Empty name]">
<P>
<BR/>
</P>
<ELECTRONIC_SEARCHES MODIFIED="2009-04-26 12:32:47 +0100" MODIFIED_BY="[Empty name]">
<P>We identified trials from the following databases:</P>
<OL>
<LI>Cochrane Controlled Trials Register (Central/CCTR in The Cochrane Library, Issue 4, 2007);</LI>
<LI>MEDLINE (1966 to December 2007);</LI>
<LI>EMBASE (1974 to December 2007);</LI>
<LI>Clinical Trials Database of the United States National Institute of Health (December 2007)</LI>
</OL>
<P>For MEDLINE and Cochrane Controlled Trials Register, we used the following MeSH search strategy:<BR/>
</P>
<P>1. huntington/all subheadings<BR/>2. chorea/all subheadings<BR/>3. drug therapy<BR/>4. prevention and control<BR/>5. rehabilitation<BR/>6. surgery<BR/>7. therapy<BR/>8. psychology<BR/>9. mortality<BR/>10. #1,2 AND #3<BR/>11. #1,2 AND #4<BR/>12. #1,2 AND #5<BR/>13. #1,2 AND #6<BR/>14. #1,2 AND #7<BR/>15. #1,2 AND #8<BR/>16. #1,2 AND #9<BR/>17. 10-16<BR/>18. #17 AND limit: clinical trial<BR/>19. in humans</P>
<P>No language restriction was applied. If necessary, the translation of the original article to Portuguese was done.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-01-19 04:15:00 +0000" MODIFIED_BY="[Empty name]">
<P>We also:</P>
<OL>
<LI>Searched referenced lists of identified trials and HD review articles;</LI>
<LI>Hand searched the Movement Disorders Journal and abstract books of international congresses of movement disorders and dementia;</LI>
<LI>Personally contacted other researchers in the field;</LI>
<LI>Contacted drug manufacturers in order to obtain additional information on trials identified in other sources or unpublished trials.</LI>
</OL>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-04-26 13:38:24 +0100" MODIFIED_BY="[Empty name]">
<P>The studies identified by the search strategy were independently assessed by two of the authors (Mestre T, Ferreira J) in terms of eligibility. Disagreements about study inclusion were resolved by consensus between Mestre T, Ferreira J and a third party (Coelho M).</P>
<P>The selected studies were independently assessed for methodological quality by two of the authors (Mestre T, Ferreira J) according to the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Cochrane-2008" TYPE="REFERENCE">Cochrane 2008</LINK>). Data analyses were recorded regarding randomisation methods, treatment and assessment blinding, comparability of treatment groups in terms of demographic and clinical characteristics (age of onset, disease duration and severity, CAG repeat expansion, co-morbidity, concomitant medication), inclusion and exclusion criteria, number of drop-outs or losses to follow-up and corresponding causes, duration of follow-up, definition of outcomes, use of validated scales and description of adverse events. The Jadad score was used as a global measure for methodological quality (<LINK REF="REF-Jadad-1996" TYPE="REFERENCE">Jadad 1996</LINK>). We decided to exclude trials with a Jadad score &lt;3.</P>
<P>Possible sources of bias were considered, namely: 1) selection bias, including randomisation and random difference between groups due to small sample size; 2) performance bias; 3) attrition bias; 4) detection bias, including modification of validated rating scales; 5) selective report of results.</P>
<P>Two of the authors (Mestre T, Ferreira J) independently registered eligible data onto standardised forms and cross checked them for accuracy. Disagreements between authors were resolved by consensus between Mestre T, Ferreira J and a third party (Coelho M). When appropriate, data from within and between studies were pooled. Accordingly, we calculated the mean difference for continuous outcomes measured with the same scale and the standardised mean difference for continuous outcomes measured on different scales. A random-effects model was used. Clinical and statistical heterogeneity was explored considering the methodological quality of the trials, treatment variations and comparability of participants. In most cases a pooled-data analysis was not possible, thus a descriptive summary of the results for each study was provided. When feasible, an intention-to-treat analysis was conducted. The number of patients in each allocated treatment group for each outcome event was always sought, regardless of compliance and patient ineligibility or exclusion after randomisation. If data were unavailable in the original publication, we contacted the principal investigator of the trial to obtain additional information. If needed, the effect of missing outcomes due to patient exclusion after randomisation would be evaluated by means of a best- and worst-case sensitivity analysis. Statistical analysis was performed using the statistical tools incorporated in the software Revman 5.0.15 (<LINK REF="REF-Revman-2008" TYPE="REFERENCE">Revman 2008</LINK>).<BR/>
</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-04-26 13:59:45 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2009-04-26 13:46:58 +0100" MODIFIED_BY="[Empty name]">
<P>The 22 included trials compared multiple pharmacological interventions with placebo. A total of 1254 patients were included; 765 patiens took the active substance and 651 patients took placebo. The initial search strategy resulted in 102 studies (1932 HD patients). The assessment of their eligibility based on the information extractable from the corresponding title and abstract contents led to the exclusion of 80 trials.The reasons were the following: open label design (n = 31, 317/16,4% participants), reduced sample dimension, i.e., n &lt; 10 (n = 34, 199/10,3% participants), absence of control (n = 5, 86/4,4% participants), , no-randomisation (n = 3, 32 participants), case series (n = 4, 14 participants), inadequate blinding (n  = 1, 12 participants), Jadad score &lt; 3 (n = 1, 12 participants) and absence of clinical outcome measures (n = 1, 6 participants) (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="3">TRIAL DESIGN:</HEADING>
<P>Nine trials had a cross-over design (<LINK REF="STD-Consroe-P" TYPE="STUDY">Consroe P</LINK>; <LINK REF="STD-De-Roover--J" TYPE="STUDY">De Roover J</LINK>; <LINK REF="STD-Goetz-CG" TYPE="STUDY">Goetz CG</LINK> ; <LINK REF="STD-Mateo-D" TYPE="STUDY">Mateo D</LINK>; <LINK REF="STD-Murman-DL" TYPE="STUDY">Murman DL</LINK>; <LINK REF="STD-O_x0027_Suilleabhain-P" TYPE="STUDY">O'Suilleabhain P</LINK>; <LINK REF="STD-Quinn-N" TYPE="STUDY">Quinn N</LINK>; <LINK REF="STD-Roos-RA" TYPE="STUDY">Roos RA</LINK>; <LINK REF="STD-Verhagen-Metman-L" TYPE="STUDY">Verhagen Metman L</LINK>) and 13 had a parallel design (<LINK REF="STD-Como-PG" TYPE="STUDY">Como PG</LINK>; <LINK REF="STD-Cubo-E" TYPE="STUDY">Cubo E</LINK>; <LINK REF="STD-Hersch-G" TYPE="STUDY">Hersch G</LINK>; <LINK REF="STD-INTRO_x002d_HD" TYPE="STUDY">INTRO-HD</LINK>; <LINK REF="STD-Kieburtz-K" TYPE="STUDY">Kieburtz K</LINK>; <LINK REF="STD-Miraxion_x002d_Europe" TYPE="STUDY">Miraxion-Europe</LINK>; <LINK REF="STD-MINO" TYPE="STUDY">MINO</LINK>; <LINK REF="STD-RID_x002d_HD" TYPE="STUDY">RID-HD</LINK>; <LINK REF="STD-Stocchi-F" TYPE="STUDY">Stocchi F</LINK>; <LINK REF="STD-TETRA_x002d_HD" TYPE="STUDY">TETRA-HD</LINK>; <LINK REF="STD-TREND_x002d_HD" TYPE="STUDY">TREND-HD</LINK>; <LINK REF="STD-Vaddadi-K" TYPE="STUDY">Vaddadi K</LINK>; <LINK REF="STD-van-Vugt-J" TYPE="STUDY">van Vugt J</LINK>). In five cross-over trials there was a wash-out period between active and placebo periods (<LINK REF="STD-Consroe-P" TYPE="STUDY">Consroe P</LINK>; <LINK REF="STD-Goetz-CG" TYPE="STUDY">Goetz CG</LINK>; <LINK REF="STD-Mateo-D" TYPE="STUDY">Mateo D</LINK>; <LINK REF="STD-Murman-DL" TYPE="STUDY">Murman DL</LINK>; <LINK REF="STD-Quinn-N" TYPE="STUDY">Quinn N</LINK>). In one of the cross-over trials without washout period (<LINK REF="STD-De-Roover--J" TYPE="STUDY">De Roover J</LINK>), the carry-over effect or the influence of period sequence was not calculated. In two other trials, a pharmacokinetic reason was given for not incorporating a washout period (<LINK REF="STD-Stocchi-F" TYPE="STUDY">Stocchi F</LINK>; <LINK REF="STD-Verhagen-Metman-L" TYPE="STUDY">Verhagen Metman L</LINK>). This was judged acceptable by the reviewers.</P>
<P>
<BR/>Fourteen trials were conducted in a single centre and eight trials were multicentric (<LINK REF="STD-Como-PG" TYPE="STUDY">Como PG</LINK>; <LINK REF="STD-Hersch-G" TYPE="STUDY">Hersch G</LINK>; <LINK REF="STD-INTRO_x002d_HD" TYPE="STUDY">INTRO-HD</LINK>; <LINK REF="STD-MINO" TYPE="STUDY">MINO</LINK>; <LINK REF="STD-Miraxion_x002d_Europe" TYPE="STUDY">Miraxion-Europe</LINK>; <LINK REF="STD-RID_x002d_HD" TYPE="STUDY">RID-HD</LINK>; <LINK REF="STD-TETRA_x002d_HD" TYPE="STUDY">TETRA-HD</LINK>; <LINK REF="STD-TREND_x002d_HD" TYPE="STUDY">TREND-HD</LINK>). Study duration ranged between 2 weeks and 80 weeks (average: 10.0 ± 7.4 weeks). Trials were published between 1982 and 2007, all of them in English, with the exception of one written in Spanish (<LINK REF="STD-Mateo-D" TYPE="STUDY">Mateo D</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">PARTICIPANTS:</HEADING>
<P>The mean age of patients was 48.4 years, ranging from 43.6 to 53.0 years of age across 19 of the included trials. The age of patients was not available in three trials (<LINK REF="STD-Miraxion_x002d_Europe" TYPE="STUDY">Miraxion-Europe</LINK>; <LINK REF="STD-TREND_x002d_HD" TYPE="STUDY">TREND-HD</LINK>; <LINK REF="STD-Verhagen-Metman-L" TYPE="STUDY">Verhagen Metman L</LINK>). Included patients had a mean of disease duration of 6.3 years, ranging from 2.3 to 9.6 years. Disease duration was not available in five trials (<LINK REF="STD-Miraxion_x002d_Europe" TYPE="STUDY">Miraxion-Europe</LINK>; <LINK REF="STD-Roos-RA" TYPE="STUDY">Roos RA</LINK>; <LINK REF="STD-TREND_x002d_HD" TYPE="STUDY">TREND-HD</LINK>; <LINK REF="STD-Vaddadi-K" TYPE="STUDY">Vaddadi K</LINK>; <LINK REF="STD-Verhagen-Metman-L" TYPE="STUDY">Verhagen Metman L</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">INTERVENTIONS:</HEADING>
<P>The following pharmacological interventions were found: Amantadine (<LINK REF="STD-O_x0027_Suilleabhain-P" TYPE="STUDY">O'Suilleabhain P</LINK>; <LINK REF="STD-Verhagen-Metman-L" TYPE="STUDY">Verhagen Metman L</LINK>), Cannabidiol (<LINK REF="STD-Consroe-P" TYPE="STUDY">Consroe P</LINK>), Clozapine (<LINK REF="STD-van-Vugt-J" TYPE="STUDY">van Vugt J</LINK>), creatine (<LINK REF="STD-Hersch-G" TYPE="STUDY">Hersch G</LINK>), Donepezil (<LINK REF="STD-Cubo-E" TYPE="STUDY">Cubo E</LINK>), ethyl-eicosapentaenoic acid (<LINK REF="STD-Miraxion_x002d_Europe" TYPE="STUDY">Miraxion-Europe</LINK>; <LINK REF="STD-TREND_x002d_HD" TYPE="STUDY">TREND-HD</LINK>), Fluoxetine (<LINK REF="STD-Como-PG" TYPE="STUDY">Como PG</LINK>), Ketamine (<LINK REF="STD-Murman-DL" TYPE="STUDY">Murman DL</LINK>), L-acetyl carnitine (<LINK REF="STD-Goetz-CG" TYPE="STUDY">Goetz CG</LINK>), Minocycline (<LINK REF="STD-MINO" TYPE="STUDY">MINO</LINK>), OPC-14117 (<LINK REF="STD-INTRO_x002d_HD" TYPE="STUDY">INTRO-HD</LINK>), Piracetam (<LINK REF="STD-Mateo-D" TYPE="STUDY">Mateo D</LINK>), Remacemide (<LINK REF="STD-Kieburtz-K" TYPE="STUDY">Kieburtz K</LINK>), Riluzole (<LINK REF="STD-RID_x002d_HD" TYPE="STUDY">RID-HD</LINK>), Sulpiride (<LINK REF="STD-Quinn-N" TYPE="STUDY">Quinn N</LINK>), Tetrabenazine (<LINK REF="STD-TETRA_x002d_HD" TYPE="STUDY">TETRA-HD</LINK>), Tiapride (<LINK REF="STD-Roos-RA" TYPE="STUDY">Roos RA</LINK>; <LINK REF="STD-De-Roover--J" TYPE="STUDY">De Roover J</LINK>), Trans-dihydrolisuride (<LINK REF="STD-Stocchi-F" TYPE="STUDY">Stocchi F</LINK>) and unsaturated fatty acids (<LINK REF="STD-Vaddadi-K" TYPE="STUDY">Vaddadi K</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">OUTCOME MEASURES:</HEADING>
<P>In eight trials the primary outcome measure was defined as the control of a motor symptom, specifically, chorea using the UHDRS motor scale (<LINK REF="STD-Cubo-E" TYPE="STUDY">Cubo E</LINK>; <LINK REF="STD-RID_x002d_HD" TYPE="STUDY">RID-HD</LINK>; <LINK REF="STD-TETRA_x002d_HD" TYPE="STUDY">TETRA-HD</LINK>; <LINK REF="STD-Verhagen-Metman-L" TYPE="STUDY">Verhagen Metman L</LINK>), the Marsden and Quinn scale (<LINK REF="STD-Consroe-P" TYPE="STUDY">Consroe P</LINK>) or a 24-point scale for which the inter-rater validity was assessed (<LINK REF="STD-O_x0027_Suilleabhain-P" TYPE="STUDY">O'Suilleabhain P</LINK>). A reduced form of the Total Motor Score-UHDRS (TMS-4) was also used (<LINK REF="STD-Miraxion_x002d_Europe" TYPE="STUDY">Miraxion-Europe</LINK>; <LINK REF="STD-TREND_x002d_HD" TYPE="STUDY">TREND-HD</LINK>). In one trial the primary outcome measure was the improvement of cognitive function measured using a cognitive testing battery (<LINK REF="STD-Murman-DL" TYPE="STUDY">Murman DL</LINK>). Functional capacity (TFC-UHDRS) was used in one study (<LINK REF="STD-Como-PG" TYPE="STUDY">Como PG</LINK>). Another primary outcome measure was safety and/or tolerability (<LINK REF="STD-Hersch-G" TYPE="STUDY">Hersch G</LINK>; <LINK REF="STD-INTRO_x002d_HD" TYPE="STUDY">INTRO-HD</LINK>; <LINK REF="STD-Kieburtz-K" TYPE="STUDY">Kieburtz K</LINK>; <LINK REF="STD-MINO" TYPE="STUDY">MINO</LINK>). The primary outcome measure was not clearly stated in eight trials (<LINK REF="STD-De-Roover--J" TYPE="STUDY">De Roover J</LINK>; <LINK REF="STD-Goetz-CG" TYPE="STUDY">Goetz CG</LINK>; <LINK REF="STD-Mateo-D" TYPE="STUDY">Mateo D</LINK>; <LINK REF="STD-Quinn-N" TYPE="STUDY">Quinn N</LINK>; <LINK REF="STD-Roos-RA" TYPE="STUDY">Roos RA</LINK>; <LINK REF="STD-Stocchi-F" TYPE="STUDY">Stocchi F</LINK>; <LINK REF="STD-Vaddadi-K" TYPE="STUDY">Vaddadi K</LINK>; <LINK REF="STD-van-Vugt-J" TYPE="STUDY">van Vugt J</LINK>).</P>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-04-10 20:15:45 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">RANDOMISATION:</HEADING>
<P>In eight trials, the description of the randomisation methodology was incorporated in the original publication. Specifically, computer generated 2:1 unbalanced design (<LINK REF="STD-TETRA_x002d_HD" TYPE="STUDY">TETRA-HD</LINK>), a random number table with blocking (<LINK REF="STD-Verhagen-Metman-L" TYPE="STUDY">Verhagen Metman L</LINK>), computer generated blocking and stratification (<LINK REF="STD-Como-PG" TYPE="STUDY">Como PG</LINK>; <LINK REF="STD-Hersch-G" TYPE="STUDY">Hersch G</LINK>; <LINK REF="STD-MINO" TYPE="STUDY">MINO</LINK>; <LINK REF="STD-RID_x002d_HD" TYPE="STUDY">RID-HD</LINK>) and computer generated blocking (<LINK REF="STD-Miraxion_x002d_Europe" TYPE="STUDY">Miraxion-Europe</LINK>; <LINK REF="STD-TREND_x002d_HD" TYPE="STUDY">TREND-HD</LINK>). In the remaining trials only a reference to randomisation was identifiable; descriptions of the adopted methodology were absent.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">ALLOCATION CONCEALMENT:</HEADING>
<P>Allocation was described and found to be adequately concealed in seven trials (<LINK REF="STD-Miraxion_x002d_Europe" TYPE="STUDY">Miraxion-Europe</LINK>; <LINK REF="STD-O_x0027_Suilleabhain-P" TYPE="STUDY">O'Suilleabhain P</LINK>; <LINK REF="STD-RID_x002d_HD" TYPE="STUDY">RID-HD</LINK>; <LINK REF="STD-TETRA_x002d_HD" TYPE="STUDY">TETRA-HD</LINK>; <LINK REF="STD-TREND_x002d_HD" TYPE="STUDY">TREND-HD</LINK>; <LINK REF="STD-Vaddadi-K" TYPE="STUDY">Vaddadi K</LINK>;<LINK REF="STD-van-Vugt-J" TYPE="STUDY">van Vugt J</LINK>). In the remaining trials, allocation concealment was not described (<LINK REF="STD-Como-PG" TYPE="STUDY">Como PG</LINK>; <LINK REF="STD-Consroe-P" TYPE="STUDY">Consroe P</LINK>; <LINK REF="STD-Cubo-E" TYPE="STUDY">Cubo E</LINK>; <LINK REF="STD-De-Roover--J" TYPE="STUDY">De Roover J</LINK>; <LINK REF="STD-Goetz-CG" TYPE="STUDY">Goetz CG</LINK>; <LINK REF="STD-Kieburtz-K" TYPE="STUDY">Kieburtz K</LINK>; <LINK REF="STD-Hersch-G" TYPE="STUDY">Hersch G</LINK>; <LINK REF="STD-INTRO_x002d_HD" TYPE="STUDY">INTRO-HD</LINK>; <LINK REF="STD-Mateo-D" TYPE="STUDY">Mateo D</LINK>; <LINK REF="STD-MINO" TYPE="STUDY">MINO</LINK>; <LINK REF="STD-Murman-DL" TYPE="STUDY">Murman DL</LINK>; <LINK REF="STD-Quinn-N" TYPE="STUDY">Quinn N</LINK>; <LINK REF="STD-Roos-RA" TYPE="STUDY">Roos RA</LINK>; <LINK REF="STD-Stocchi-F" TYPE="STUDY">Stocchi F</LINK>; <LINK REF="STD-Verhagen-Metman-L" TYPE="STUDY">Verhagen Metman L</LINK>). The authors decided to include these trials in the present review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">SAMPLE SIZE CALCULATION:</HEADING>
<P>Sample size calculation was conducted in 13 trials (<LINK REF="STD-Consroe-P" TYPE="STUDY">Consroe P</LINK>; <LINK REF="STD-Cubo-E" TYPE="STUDY">Cubo E</LINK>; <LINK REF="STD-Kieburtz-K" TYPE="STUDY">Kieburtz K</LINK>; <LINK REF="STD-Hersch-G" TYPE="STUDY">Hersch G</LINK>; <LINK REF="STD-INTRO_x002d_HD" TYPE="STUDY">INTRO-HD</LINK>; <LINK REF="STD-MINO" TYPE="STUDY">MINO</LINK>; <LINK REF="STD-Miraxion_x002d_Europe" TYPE="STUDY">Miraxion-Europe</LINK>; <LINK REF="STD-O_x0027_Suilleabhain-P" TYPE="STUDY">O'Suilleabhain P</LINK>; <LINK REF="STD-Quinn-N" TYPE="STUDY">Quinn N</LINK>; <LINK REF="STD-RID_x002d_HD" TYPE="STUDY">RID-HD</LINK>; <LINK REF="STD-TETRA_x002d_HD" TYPE="STUDY">TETRA-HD</LINK>; <LINK REF="STD-TREND_x002d_HD" TYPE="STUDY">TREND-HD</LINK>; <LINK REF="STD-Verhagen-Metman-L" TYPE="STUDY">Verhagen Metman L</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">DATA INCLUDED:</HEADING>
<P>Ten trials analysed their results on a intention-to-treat basis (<LINK REF="STD-Goetz-CG" TYPE="STUDY">Goetz CG</LINK>; <LINK REF="STD-Hersch-G" TYPE="STUDY">Hersch G</LINK>; <LINK REF="STD-INTRO_x002d_HD" TYPE="STUDY">INTRO-HD</LINK>; <LINK REF="STD-Kieburtz-K" TYPE="STUDY">Kieburtz K</LINK>; <LINK REF="STD-Mateo-D" TYPE="STUDY">Mateo D</LINK>; <LINK REF="STD-MINO" TYPE="STUDY">MINO</LINK>; <LINK REF="STD-RID_x002d_HD" TYPE="STUDY">RID-HD</LINK>; <LINK REF="STD-Roos-RA" TYPE="STUDY">Roos RA</LINK>; <LINK REF="STD-Stocchi-F" TYPE="STUDY">Stocchi F</LINK>; <LINK REF="STD-TETRA_x002d_HD" TYPE="STUDY">TETRA-HD</LINK>); eleven trials conducted data analysis on a per-protocol basis (<LINK REF="STD-Como-PG" TYPE="STUDY">Como PG</LINK>; <LINK REF="STD-Consroe-P" TYPE="STUDY">Consroe P</LINK>; <LINK REF="STD-Cubo-E" TYPE="STUDY">Cubo E</LINK>; <LINK REF="STD-De-Roover--J" TYPE="STUDY">De Roover J</LINK>; <LINK REF="STD-Miraxion_x002d_Europe" TYPE="STUDY">Miraxion-Europe</LINK>; <LINK REF="STD-O_x0027_Suilleabhain-P" TYPE="STUDY">O'Suilleabhain P</LINK>; <LINK REF="STD-Quinn-N" TYPE="STUDY">Quinn N</LINK>; <LINK REF="STD-TREND_x002d_HD" TYPE="STUDY">TREND-HD</LINK>; <LINK REF="STD-Vaddadi-K" TYPE="STUDY">Vaddadi K</LINK>; <LINK REF="STD-van-Vugt-J" TYPE="STUDY">van Vugt J</LINK>; <LINK REF="STD-Verhagen-Metman-L" TYPE="STUDY">Verhagen Metman L</LINK>). It was not possible to determine the adopted approach in one trial (<LINK REF="STD-Murman-DL" TYPE="STUDY">Murman DL</LINK>).</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-04-26 13:59:45 +0100" MODIFIED_BY="[Empty name]">
<P>Results are expressed as mean ± standard deviation, unless otherwise indicated.</P>
<P>
<B>Anti-dopaminergic</B>. Five trials were selected (<LINK REF="STD-De-Roover--J" TYPE="STUDY">De Roover J</LINK>; <LINK REF="STD-Quinn-N" TYPE="STUDY">Quinn N</LINK>; <LINK REF="STD-Roos-RA" TYPE="STUDY">Roos RA</LINK>; <LINK REF="STD-TETRA_x002d_HD" TYPE="STUDY">TETRA-HD</LINK>; <LINK REF="STD-van-Vugt-J" TYPE="STUDY">van Vugt J</LINK>).</P>
<P>The trial (n = 84) using the monoamine-depleting agent Tetrabenazine with a dose of 100 mg/day (<LINK REF="STD-TETRA_x002d_HD" TYPE="STUDY">TETRA-HD</LINK>) reported a decrease in total maximal chorea using the UHDRS motor scale (-5.0 ± 0.5 treatment group vs. -1.5 ± 0.7 placebo group; p &lt; 0.0001) with an estimated treatment effect of a 3.5 point reduction (95 % CI: -5.2; -1.9, p &lt; 0.0001) in the chorea score (min: 0 ; max: 28) independent of age, gender, trinucleotide repeat length, gender of affected parent, baseline Clinical Global Impression (CGI) severity or baseline chorea score. A corresponding improvement in the CGI scale favouring treatment was also observed: 3.0 ± 0.2 treatment group vs. 3.7 ± 0.2 placebo group; p &lt; 0.007. However, Tetrabenazine proved to be deleterious in a statistically significant fashion for a few exploratory outcome measures, namely, the UHDRS Functional Checklist (-0.8 ± 0.3 treatment group vs. 0.4 ± 0.4 placebo group; p = 0.02), the 17-item Hamilton Depression scale (-0.7 ± 0.3 treatment group vs. -2.4 ± 0.4 placebo group; p = 0.003), the Epworth Sleepiness Scale (1.5 ± 0.5 treatment group vs. -0.3 ± 0.6 placebo group; p = 0.02), and the Stroop-word reading test (-4.8 ± 1.5 treatment group vs. 1.8 ± 2.1 placebo group; p = 0.01). Tetrabenazine was not different from placebo in the Barnes Akathisia Rating Scale nor in the remaining items of the UHDRS scale (Total Functional Capacity, Independence and Behavioural scales, Stroop colour naming and interference tests, and swallowing, speech and gait items of motor scale). The exclusive occurrence of drop-outs in the treatment group (9.2 % of treated patients, n = 5) was also relevant. Those were due to adverse events (akathisia, suicide, intracranial haemorrhage, depression/restlessness and breast cancer).</P>
<P>For the drug Sulpiride, the trial of Quinn and Marsden (<LINK REF="STD-Quinn-N" TYPE="STUDY">Quinn N</LINK>) evaluated 11 patients taking 300-1200 mg of Sulpiride/day (mean dosage: 1054 mg/day). A positive result was found for the median movement count (38 during placebo phase vs. 14 during treatment phase; p &lt; 0.01) and for the median chorea severity taking into account eight body parts (33 during placebo phase vs. 14 during treatment phase; p &lt; 0.01). However, a corresponding functional improvement was not observed (12 treatment group vs. 15 placebo group; p &gt; 0.05).</P>
<P>In one trial (n = 29) using Tiapride, 3 g/day (<LINK REF="STD-De-Roover--J" TYPE="STUDY">De Roover J</LINK>), the authors stated that Tiapride markedly improved choreic movements in 3 out of 5 body segments (head, p = 0.00; trunk , p = 0.05; upper limbs, p = 0.01; lower limbs, p = 0.01) and 3 motor skills out of 7. However, the data was presented only in a qualitative fashion and a more descriptive statistical analysis was lacking. For the remaining outcome measures (wakefulness and motor performance, anxiety, irritability, unsociability and depression) no significant difference was found between exposure to treatment and placebo. In the other trial with Tiapride, 300 mg/day, n = 22 (<LINK REF="STD-Roos-RA" TYPE="STUDY">Roos RA</LINK>) the total number of choreic movements during two minutes was not significantly different in the placebo and treatment groups if measured using a videotape (0.02 ± 0.26 Tiapride-placebo group vs. -0.26 ± 0.66 placebo-Tiapride group; p = 0.20) or a whole-body Doppler radar (0.19 ± 0.49 Tiapride-placebo group vs. -0.36 ± 0.91 placebo-Tiapride group; p = 0.10).</P>
<P>In the trial assessing Clozapine (n = 33) on a maximum dosage of 150 mg/day (<LINK REF="STD-van-Vugt-J" TYPE="STUDY">van Vugt J</LINK>) a reduction in the grade of chorea (-7.3 ± 3.4 treatment group vs. 0 ± 4.8 placebo group; p = 0.02 ) in the cohort of neuroleptic-naive patients (n = 18) was reported. By contrast, no significant reduction in chorea was found in the same group when using the UHDRS scale (-4.0 ± 3.0 treatment group vs. -0.3 ± 3.7 placebo group; p = 0.07) and patients on Clozapine scored worse on a self-evaluated disability scale (5.7 ± 9.2 treatment group vs. -3.8 ± 7.7 placebo group; p = 0.02 ). Accordingly, the authors also stated that anti-choreic effects were more evident with higher doses of Clozapine, simultaneously with a higher incidence of adverse effects. No statistically significant results were observed in the neuroleptic-treated patients group (n = 8). Results of the whole cohort were not available for analysis.<BR/>
<BR/>
<B>Anti-glutamatergic</B>. Two trials were found to study Amantadine (<LINK REF="STD-O_x0027_Suilleabhain-P" TYPE="STUDY">O'Suilleabhain P</LINK>; <LINK REF="STD-Verhagen-Metman-L" TYPE="STUDY">Verhagen Metman L</LINK>) and one trial studied Riluzole (<LINK REF="STD-RID_x002d_HD" TYPE="STUDY">RID-HD</LINK>). Phase II trials testing Remacemide (<LINK REF="STD-Kieburtz-K" TYPE="STUDY">Kieburtz K</LINK>) and Ketamine (<LINK REF="STD-Murman-DL" TYPE="STUDY">Murman DL</LINK>) were also selected. Regarding Amantadine, one trial (<LINK REF="STD-Verhagen-Metman-L" TYPE="STUDY">Verhagen Metman L</LINK>) (mean dosage: 386 mg/day in the range 100-400 mg, n = 24) reported efficacy for Amantadine in reducing median maximal chorea (18 %; range: -40 % to 68 % treatment period vs. 5 %, range: -100 % to 41.5 % placebo period; p = 0.0007) and median rest chorea (25 %; range: -150 % to 100 % treatment period vs. 5 %; range: -150 % to 71.4 % placebo period; p = 0.013). A wide variation of Amantadine concentration was suggested to explain the wide range of variability in Amantadine anti-choreic effects. In the other selected trial testing Amantadine (<LINK REF="STD-O_x0027_Suilleabhain-P" TYPE="STUDY">O'Suilleabhain P</LINK>) at a daily dose of 300 mg/day in 25 patients, the change in mean chorea score was not significantly different between groups (difference between Amantadine and placebo: 95 % CI: -1.43 to 1.0). The same was observed for proprioceptive tasks. However, in a semi-quantitative patient questionnaire a higher number of patients reported a subjective benefit on chorea (19 subjects treatment period vs. 6 placebo period; p = 0.006) and quality of life (3.9 ± 0.7 treatment period vs. -2.95 ± 0.7 placebo period; p &lt; 0.001). A meta-analysis was conducted. The results were expressed as percentage relative to the maximum score of the used scales. The pooled result does not significantly favour treatment with Amantadine for the control of chorea: the standardised mean difference for reduction of chorea intensity was -0.25 % (95 % CI -0.93, 0.43) (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>In a trial with Riluzole (n = 63) (<LINK REF="STD-RID_x002d_HD" TYPE="STUDY">RID-HD</LINK>), 100 or 200 mg/day, 200 mg/day of Riluzole showed efficacy for the selected primary outcome measure (change in total chorea score-UHDRS: -2.2 ± 3.3 Riluzole 200 mg vs. 0.7 ± 3.4 placebo group; p = 0.01) although the <I>post hoc</I> analysis evidenced the absence of significance when neuroleptic-treated patients were removed from analysis. The secondary outcome measure (change in TMS-UHDRS) was significantly different between groups (-4.0 ± 7.1 Riluzole 200 mg vs. 1.6 ± 7.4 placebo group; p = 0.03); a contribution of chorea reduction for the latter was put forward by the authors as a putative explanation. Other items of the UHDRS defined as secondary efficacy outcome measures (change in total dystonia score, Stroop interference test, independence scale) were not significantly different between treatment and placebo groups. A safety issue was raised due to a persistent and significant elevation of hepatic liver enzymes in the Riluzole group (8 cases in the group of Riluzole 100 mg/day, and 14 cases in the group of Riluzole 200 mg/day), which curtailed further investigation with Riluzole in a dose of 200 mg/day.</P>
<P>In a trial with Ketamine (n = 10) (<LINK REF="STD-Murman-DL" TYPE="STUDY">Murman DL</LINK>), 0.1, 0.4 and 0.6 mg/kg/hr, the clinical effect of NMDA blockade was studied by using increasing doses of the drug. The intermediate dose (0.4 mg/kg/hr) produced a decline in verbal and fluency memory items (immediate recall in Buschke Selective Reminding Test -4.4 ± 0.7 treatment period vs. -6.9 ± 0.2 placebo period; p &lt; 0.05, immediate and delayed recall in the Washington Square Picture Memory test and in verbal fluency test -6.2 ± 2.1 treatment period vs. 9.1 ± 1.6 placebo period; p &lt; 0.05). Higher doses (0.6 mg/kg/hr) produced behavioural symptoms (increase in the Brief Psychiatric Rating Scale total score (50.4 ± 5.7 treatment period vs. 27.1 ± 1.3 placebo period; p &lt; 0.05), anergia (3.0 ± 0.5 treatment period vs. 1.1 ± 0.0 placebo period; p &lt; 0.05), thought disorders (1.8 ±  0.3 treatment period vs. 1.1 ±  0.0 placebo period; p &lt; 0.05) and an increase in the Institute of Mental Health's Self Rating Scale total score as well as in its items of functional deficit and altered self-awareness. Deteriorations in the total motor score (21.0 ± 4.1 treatment period vs. 13.3 ± 3.0 placebo period; p &lt; 0.05) and eye movements (8.1 ± 2.5 treatment period vs. 3.9 ± 1.4 placebo period; p &lt; 0.05) measured by the UHDRS were observed.</P>
<P>The trial studying Remacemide 200 or 600 mg/day (n = 31) (<LINK REF="STD-Kieburtz-K" TYPE="STUDY">Kieburtz K</LINK>) produced negative results. A beneficial trend was reported for maximal chorea grade using Huntington Disease Motor Rating Scale (HDMRS) (1.6 ± 3.7 Remacemide 200 mg vs. 1.1 ± 2.4 placebo group; p &lt; 0.15), for three immediate-recall trials of Hopkins Verbal Learning Test (1.4 ± 2.0 (trial 1) and 0.9 ± 1.3 (trial 2) Remacemide 200 mg vs. 0.2 ± 1.3 (trial 1) and 0.5 ± 1.0 (trial 2) placebo group; p &lt; 0.10), and the Stroop colour naming test (0.04 ± 0.14 Remacemide 200 mg vs. 0.07 ± 0.13 placebo group; p &lt; 0.17). Other assessments of frontal lobe function, depression and functional capacity using the Huntington Disease Functional Capacity Scale (HDFCS) produced non-significant difference between groups.</P>
<P>
<B>Energy metabolite.</B>
</P>
<P>Trials with ethyl-eicosapentaenoic acid (<LINK REF="STD-Miraxion_x002d_Europe" TYPE="STUDY">Miraxion-Europe</LINK>; <LINK REF="STD-TREND_x002d_HD" TYPE="STUDY">TREND-HD</LINK>) and with unsaturated fatty acids (<LINK REF="STD-Vaddadi-K" TYPE="STUDY">Vaddadi K</LINK>) were included. Phase II trials of L-acetyl carnitine (<LINK REF="STD-Goetz-CG" TYPE="STUDY">Goetz CG</LINK>) and creatine (<LINK REF="STD-Hersch-G" TYPE="STUDY">Hersch G</LINK>) were also selected. Globally, only the trial assessing the use of unsaturated fatty acids (8 g/day, n = 19)(<LINK REF="STD-Vaddadi-K" TYPE="STUDY">Vaddadi K</LINK> ) reported positive results. Specifically, a reduction in dyskinesia measured by the Rockland-Simpson Dyskinesia Rating scale (RSDS): -4.3 ± 2.1 treatment group vs. 7.0 ± 3.7 placebo group; p = 0.01. Nevertheless, the latter was not considered a primary outcome measure. No treatment effect was reported in the remaining efficacy outcome measures: change in TMS-UHDRS: -3.4 ± 4.0 treatment group vs. 10.3 ± 4.7 placebo group, p = 0.08, and change in combined UHDRS functional and cognitive scores: -1.3 ± 2.0 treatment group vs. 5.4 ± 2.1 placebo group, p = 0.08. In the two trials studying ethyl-eicosapentaenoic acid, 2 g/day, n = 290 (<LINK REF="STD-Miraxion_x002d_Europe" TYPE="STUDY">Miraxion-Europe</LINK>) and n = 316 (<LINK REF="STD-TREND_x002d_HD" TYPE="STUDY">TREND-HD</LINK>) no significant effect was observed for the primary efficacy outcome measure, i.e., the effect on motor phenotype as measured by the reduced version of the total motor score of UHDRS (TMS-4). Regarding the <LINK REF="STD-TREND_x002d_HD" TYPE="STUDY">TREND-HD</LINK> trial, a 0.2 point worsening in treatment group vs. 1.0 point worsening in placebo group (p = 0.21) was observed using the same scale. In the sub-group analysis (CAG repeat&lt;45) the TMS-4 was also not different between the ethyl-eicosapentaenoic acid group (0.0 point) and the placebo group (0.3 point; p = 0.68).</P>
<P>In the trial of <LINK REF="STD-Goetz-CG" TYPE="STUDY">Goetz CG</LINK> (n = 10) the acute effect of L-acetyl carnitine, 45 mg/kg/day, was studied. Measures of disability (Shoulson-Fahn Disability scale), abnormal movements (Abnormal Involuntary Movements Scale and reaction time), dementia (MMSE, Controlled Oral World association) and depression (Hamilton Depression scale) were not significantly different in placebo and treatment groups. </P>
<P>In the creatine trial (<LINK REF="STD-Hersch-G" TYPE="STUDY">Hersch G</LINK>), 8 mg/day, n = 64, in all the selected secondary efficacy outcome measures there was no difference between placebo and treatment groups. Those outcome measures comprehended sub-items of UHDRS scale such as total chorea score, total motor score, verbal fluency test, symbol digit test, and Stroop interference test. No statistical significance was presented.</P>
<P>
<B>Free-radical scavenger. </B>In a phase II trial testing OPC-14117, 60-120-240 mg/day, n = 64 (<LINK REF="STD-INTRO_x002d_HD" TYPE="STUDY">INTRO-HD</LINK>), no difference was found between treatment and placebo groups on the defined efficacy outcome measures (change in total score of UHDRS and its sub-items, executive function measured by neuropsychological tests and depression measured by the Beck Depression Inventory).<BR/>
<B>
<BR/>Others</B>.Trials with Cannabidiol (<LINK REF="STD-Consroe-P" TYPE="STUDY">Consroe P</LINK>), Donepezil (<LINK REF="STD-Cubo-E" TYPE="STUDY">Cubo E</LINK>), Fluoxetine (<LINK REF="STD-Como-PG" TYPE="STUDY">Como PG</LINK>), Minocycline (<LINK REF="STD-MINO" TYPE="STUDY">MINO</LINK>), Piracetam (<LINK REF="STD-Mateo-D" TYPE="STUDY">Mateo D</LINK>), and trans-dyhidrolisuride (<LINK REF="STD-Stocchi-F" TYPE="STUDY">Stocchi F</LINK>) were included. All trials were negative for efficacy outcome measures.</P>
<P>In the trial of <LINK REF="STD-Consroe-P" TYPE="STUDY">Consroe P</LINK>, Cannabidiol 10 mg/kg/day, n = 18, non-significant changes were obtained in chorea severity (Marsden and Quinn scale; 11.2 ± 1.4 placebo period vs. 11.4 ± 1.4 treatment period; p = 0.71) and in functional capacity (Shoulson and Fahn functional disability scale; 6.7 ± 0.6 placebo period vs. 6.9 ± 0.5 treatment period; p = 0.14)and HD staging system; 2.9 ± 0.1 placebo period vs. 3.0 ± 0.1 treatment period; p = 0.18). In a variety of other tests measuring motor function, cognition and psychological distress (SLC-90R) no difference was found between treatment and placebo periods.</P>
<P>In the trial of <LINK REF="STD-Cubo-E" TYPE="STUDY">Cubo E</LINK>, Donepezil (10 mg/day, n = 30) no significant improvement was observed for the primary outcome. i.e., chorea, using the UHDRS. Similar results were observed for the selected secondary outcomes, i.e., total motor score of UHDRS, bradykinesia (UHDRS) and measures of cognition and quality of life (modified Sickness Impact Profile). Nevertheless, the authors reported a trend in favour of d for the UHDRS functional checklist: median [range], 0 [-5 to 3] placebo group vs. 0.5 [0 to 3] treatment group, p = 0.051.</P>
<P>For the Fluoxetine trial (<LINK REF="STD-Como-PG" TYPE="STUDY">Como PG</LINK>), Fluoxetine 20 mg/day, n = 30, the outcome functional capacity (TFC-UHDRS) was not statistically different between groups (0.09 ± 2.0 placebo group vs. 0.25 ± 2.7 treatment group; p = 0,78). A similar result was obtained for other motor and cognitive outcomes. Only for the item agitation of the Cognitive Behaviour Rating Scale, a significant different result was reported (-5.56 ± 11.7 placebo group vs. 8.73 ± 12.0 treatment group; p = 0.02).</P>
<P>In a trial testing Piracetam (<LINK REF="STD-Mateo-D" TYPE="STUDY">Mateo D</LINK>), 12 g, n = 11, the active substance was found to worsen involuntary movements 4 hours after drug administration as measured by the Kartzinel, Hunt, Calne scale.</P>
<P>In the trial conducted using trans-dyhidrolisuride, 5 mg/day, n = 10 (<LINK REF="STD-Stocchi-F" TYPE="STUDY">Stocchi F</LINK>), no significant results were obtained for the selected outcome measures: disease severity (Marsden and Quinn scale), involuntary movements (AIMS scale), dementia (MMSE) and quantification of rapid wrist movements using an EMG-based methodology.</P>
<P>The trial studying Minocycline (<LINK REF="STD-MINO" TYPE="STUDY">MINO</LINK>),100 or 200 mg/day, n = 60, assessed the change in the TMS-UHDRS and in the cognitive and functional components of UHDRS. A significant difference was only observed in the Stroop interference test with the treatment group performing worse: 1.87 ± 4.83 placebo group vs. 1.50 ± 6.68 Minocycline 100 mg/day vs. -3.42 ± 10.5 Minocycline 200 mg/day; p = 0.04.</P>
<P>
<B>
<BR/>Adverse events and safety. </B>With the exception of two trials (<LINK REF="STD-Consroe-P" TYPE="STUDY">Consroe P</LINK>; <LINK REF="STD-Mateo-D" TYPE="STUDY">Mateo D</LINK>), adverse events were reported<B>. </B>In fourteen trials, the occurrence or absence of serious adverse events was reported in both treatment and control groups (<LINK REF="STD-Como-PG" TYPE="STUDY">Como PG</LINK>; <LINK REF="STD-De-Roover--J" TYPE="STUDY">De Roover J</LINK>; <LINK REF="STD-Goetz-CG" TYPE="STUDY">Goetz CG</LINK>; <LINK REF="STD-Kieburtz-K" TYPE="STUDY">Kieburtz K</LINK>; <LINK REF="STD-INTRO_x002d_HD" TYPE="STUDY">INTRO-HD</LINK>; <LINK REF="STD-Mateo-D" TYPE="STUDY">Mateo D</LINK>; <LINK REF="STD-O_x0027_Suilleabhain-P" TYPE="STUDY">O'Suilleabhain P</LINK>; <LINK REF="STD-Quinn-N" TYPE="STUDY">Quinn N</LINK> ;<LINK REF="STD-RID_x002d_HD" TYPE="STUDY">RID-HD</LINK>; <LINK REF="STD-Roos-RA" TYPE="STUDY">Roos RA</LINK>; <LINK REF="STD-Stocchi-F" TYPE="STUDY">Stocchi F</LINK>; <LINK REF="STD-TETRA_x002d_HD" TYPE="STUDY">TETRA-HD</LINK>; <LINK REF="STD-van-Vugt-J" TYPE="STUDY">van Vugt J</LINK>; <LINK REF="STD-Verhagen-Metman-L" TYPE="STUDY">Verhagen Metman L</LINK>). In four of those trials, serious adverse events were observed exclusively in the treatment group (<LINK REF="STD-INTRO_x002d_HD" TYPE="STUDY">INTRO-HD</LINK>; <LINK REF="STD-RID_x002d_HD" TYPE="STUDY">RID-HD</LINK>; <LINK REF="STD-TETRA_x002d_HD" TYPE="STUDY">TETRA-HD</LINK>; <LINK REF="STD-van-Vugt-J" TYPE="STUDY">van Vugt J</LINK>). Three trials did not provide a report of serious adverse events occurrence (<LINK REF="STD-Consroe-P" TYPE="STUDY">Consroe P</LINK>; <LINK REF="STD-Murman-DL" TYPE="STUDY">Murman DL</LINK>; <LINK REF="STD-Vaddadi-K" TYPE="STUDY">Vaddadi K</LINK>). Overall, there were a total of 51 (6.1 %) drop-outs during inclusion in treatment groups and 22 (3.4 %) drop-outs during inclusion in the placebo groups. No drop-outs were observed in five trials (<LINK REF="STD-Goetz-CG" TYPE="STUDY">Goetz CG</LINK>; <LINK REF="STD-Mateo-D" TYPE="STUDY">Mateo D</LINK>; <LINK REF="STD-Murman-DL" TYPE="STUDY">Murman DL</LINK>; <LINK REF="STD-Roos-RA" TYPE="STUDY">Roos RA</LINK>; <LINK REF="STD-Stocchi-F" TYPE="STUDY">Stocchi F</LINK>;). In 14 trials, drop-outs were related to adverse events (<LINK REF="STD-Como-PG" TYPE="STUDY">Como PG</LINK>; <LINK REF="STD-Cubo-E" TYPE="STUDY">Cubo E</LINK>; <LINK REF="STD-De-Roover--J" TYPE="STUDY">De Roover J</LINK>; <LINK REF="STD-Goetz-CG" TYPE="STUDY">Goetz CG</LINK>; <LINK REF="STD-Kieburtz-K" TYPE="STUDY">Kieburtz K</LINK>; <LINK REF="STD-Hersch-G" TYPE="STUDY">Hersch G</LINK>; <LINK REF="STD-INTRO_x002d_HD" TYPE="STUDY">INTRO-HD</LINK>; <LINK REF="STD-MINO" TYPE="STUDY">MINO</LINK>; <LINK REF="STD-O_x0027_Suilleabhain-P" TYPE="STUDY">O'Suilleabhain P</LINK>; <LINK REF="STD-Quinn-N" TYPE="STUDY">Quinn N</LINK>; <LINK REF="STD-RID_x002d_HD" TYPE="STUDY">RID-HD</LINK>; <LINK REF="STD-TETRA_x002d_HD" TYPE="STUDY">TETRA-HD</LINK>; <LINK REF="STD-Vaddadi-K" TYPE="STUDY">Vaddadi K</LINK>; <LINK REF="STD-van-Vugt-J" TYPE="STUDY">van Vugt J</LINK>) with a median per-trial frequency of 80 % (range: 0-100 %) and 58 % (range: 0-100 %)<I>
<B> </B>
</I>for treatment and control groups, respectively. Concerning the trials with safety and tolerability as primary outcomes measures, L-acetyl carnitine was very well tolerated with no serious adverse events, or drop-out due to adverse events (<LINK REF="STD-Goetz-CG" TYPE="STUDY">Goetz CG</LINK>). Minocycline (<LINK REF="STD-MINO" TYPE="STUDY">MINO</LINK>), Remacemide (<LINK REF="STD-Kieburtz-K" TYPE="STUDY">Kieburtz K</LINK>) and creatine (<LINK REF="STD-Hersch-G" TYPE="STUDY">Hersch G</LINK>) were generally well tolerated and safe. OPC-14117 (<LINK REF="STD-INTRO_x002d_HD" TYPE="STUDY">INTRO-HD</LINK>) was associated with frequent drop-outs (12.5 %; n = 8), all related to adverse events.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-04-26 14:03:45 +0100" MODIFIED_BY="[Empty name]">
<P>Regarding the symptomatic control of HD, the present review shows that anti-dopaminergic agents, glutamate antagonists and one energy metabolite seem to have a positive effect for motor symptoms. Trials with Tetrabenazine (<LINK REF="STD-TETRA_x002d_HD" TYPE="STUDY">TETRA-HD</LINK>), amantadine (<LINK REF="STD-Verhagen-Metman-L" TYPE="STUDY">Verhagen Metman L</LINK>), Riluzole (<LINK REF="STD-RID_x002d_HD" TYPE="STUDY">RID-HD</LINK>) and unsaturated fatty acids (<LINK REF="STD-Vaddadi-K" TYPE="STUDY">Vaddadi K</LINK>) used validated scales, namely, the UHDRS motor scale (<LINK REF="STD-RID_x002d_HD" TYPE="STUDY">RID-HD</LINK>; <LINK REF="STD-TETRA_x002d_HD" TYPE="STUDY">TETRA-HD</LINK>; <LINK REF="STD-Verhagen-Metman-L" TYPE="STUDY">Verhagen Metman L</LINK>) and the RSDRS (<LINK REF="STD-Vaddadi-K" TYPE="STUDY">Vaddadi K</LINK>). The remaining trials testing medications belonging to the same pharmacological classes were negative and/or presented serious methodological constraints. In the trial with clozapine (<LINK REF="STD-van-Vugt-J" TYPE="STUDY">van Vugt J</LINK>) results from the original cohort were not available and the putative anti-choreic effect of Clozapine was not consistent across the two scales used for that purpose, i.e. AIMS, and UHDRS-chorea score. In the trial by <LINK REF="STD-De-Roover--J" TYPE="STUDY">De Roover J</LINK> methodological issues were also raised: this was a cross-over study but no washout between treatment and placebo periods was adopted, and the carry-over effect was not calculated. The trial with Sulpiride (<LINK REF="STD-Quinn-N" TYPE="STUDY">Quinn N</LINK>) did not use a validated scale.</P>
<P>In the aforementioned trials reporting significant positive results, the Tetrabenazine trial (<LINK REF="STD-TETRA_x002d_HD" TYPE="STUDY">TETRA-HD</LINK>) presented less methodological flaws, used a larger patient sample and was able to show a more robust anti-choreic effect than the other trials. Nevertheless, Tetrabenazine-treated patients performed worse in functional outcome measures and serious adverse events occurred exclusively in the treatment group. These aspects should be weighed in the assessment of its overall effectiveness and when using Tetrabenazine in the clinical management of chorea in HD patients. Regarding Amantadine, although one trial reported positive results (<LINK REF="STD-Verhagen-Metman-L" TYPE="STUDY">Verhagen Metman L</LINK>), the other selected trial (<LINK REF="STD-O_x0027_Suilleabhain-P" TYPE="STUDY">O'Suilleabhain P</LINK>) with a similar cross-over design rendered opposite results. The pool-data analysis demonstrated the existence of a non-significant anti-choreic effect. As for Riluzole, its efficacy was only demonstrated in the 200 mg/day group, a dosage associated with an excess of hepatic toxicity, which advises against its clinical use at that daily dose. Recently, a trial using similar outcome measures but with disease-modifying objectives unequivocally demonstrated the lack of efficacy of Riluzole 100 mg/day for the treatment of HD patients (<LINK REF="REF-EHDN-2007" TYPE="REFERENCE">EHDN 2007</LINK>). Regarding unsaturated fatty acids, the anti-dyskinetic effect reported by the authors must be put into perspective with more recent trials (<LINK REF="STD-Miraxion_x002d_Europe" TYPE="STUDY">Miraxion-Europe</LINK>; <LINK REF="STD-TREND_x002d_HD" TYPE="STUDY">TREND-HD</LINK>) showing that ethyl-eicosapentaenoic acid was not effective in the control of chorea and other motor symptoms. Ethyl-eicosapentaenoic acid was one of the unsaturated fatty acids mixtures used by <LINK REF="STD-Vaddadi-K" TYPE="STUDY">Vaddadi K</LINK> .</P>
<P>Finally, the analysis of the used outcome measures shows that non-motor symptoms have not been specifically addressed in HD interventional studies. In fact, none of the selected trials was primarily conducted to study therapeutic effects on the control of psychiatric symptoms or cognitive decline, which have a significant effect on the quality of life of the patient with HD and his/her next of kin or caregiver.</P>
<P>
<BR/>
</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-04-26 14:04:20 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2009-04-26 14:04:20 +0100" MODIFIED_BY="[Empty name]">
<P>No intervention has proven to have a consistent symptomatic control in HD. The current review regards Tetrabenazine as the anti-choreic medication with best available clinical evidence. Nevertheless, only one trial has been included in the present systematic review. No statement can be made regarding the effectiveness of available medication in other areas of symptomatic control due to the lack of evidence extractable from clinical trials. </P>
<P>No statement can be made regarding the best medical practice for the control of motor and non-motor symptoms in HD.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-03-05 13:48:21 +0000" MODIFIED_BY="Ema Roque">
<P>Further double-blind, randomised, placebo-controlled trials adequately powered must be conducted to study the effectiveness of therapeutic interventions for the symptomatic control of HD, not only for motor symptoms but also for other symptomatic areas. The efficacy of therapeutic interventions previously shown to be safe in the symptomatic treatment of HD should be studied by conducting properly sampled clinical trials.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-01-19 04:17:15 +0000" MODIFIED_BY="[Empty name]">
<P>We thank Dr. Padraig O'Suilheabhain, Dr. Leo Verhagen-Metman, Dr. Jeroen van Vugt and Professor Raymond Roos for supplying original unpublished data. We also thank Dr. Frederick Marshal and Professor Krishna Vaddadi for answering our questions regarding methodological issues of related trials.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-04-10 20:44:23 +0100" MODIFIED_BY="[Empty name]">
<P>Mestre T, Ferreira J, Coelho M, Rosa MM were investigators in a clinical trial to investigate the efficacy of ethyl-EPA for the treatment of HD.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-04-26 14:04:53 +0100" MODIFIED_BY="[Empty name]">
<P>Protocol - Ferreira J, Mestre T, Sampaio C.<BR/>Literature search - Ferreira J, Mestre T, Coelho M.<BR/>Literature selection - Ferreira J, Mestre T, Coelho M.<BR/>Papers quality assessment - Ferreira J, Mestre T.<BR/>Data collection from papers - Ferreira J, Mestre T.<BR/>Interpretation of data - Ferreira J, Mestre T, Coelho M, Rosa MM, Sampaio C.<BR/>Review writing - Mestre T, Ferreira J, Sampaio C.<BR/>
</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-04-26 15:22:45 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2009-04-26 15:22:45 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-04-26 15:22:45 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Como-PG" NAME="Como PG" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Como PG, Rubin AJ, O'Brien CF, Lawler K, Hickey C, Rubin AE, et al</AU>
<TI>A controlled trial of fluoxetine in nondepressed patients with Huntington's disease</TI>
<SO>Mov Disord 1997;12(3):397-401</SO>
<YR>1997</YR>
<VL>12</VL>
<NO>3</NO>
<PG>397-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Consroe-P" NAME="Consroe P" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, et al</AU>
<TI>Controlled clinical trial of cannabidiol in Huntington's disease</TI>
<SO>Pharmacol Biochem Behav</SO>
<YR>1991</YR>
<VL>40</VL>
<NO>3</NO>
<PG>701-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cubo-E" MODIFIED="2008-11-08 05:18:28 +0000" MODIFIED_BY="[Empty name]" NAME="Cubo E" YEAR="2006">
<REFERENCE MODIFIED="2008-11-08 05:18:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cubo E, Shannon KM, Tracy D, Jaglin JA, Bernard BA, Wuu J, Leurgans SE</AU>
<TI>Effect of donepezil on motor and cognitive function in Huntington disease</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>10</VL>
<NO>7</NO>
<PG>1268-71</PG>
<IDENTIFIERS MODIFIED="2008-11-08 05:18:28 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-08 05:18:28 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1212/01.wnl.0000238106.10423.00"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-11-08 05:15:52 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-08 05:15:52 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1212/01.wnl.0000238106.10423.00"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-De-Roover--J" NAME="De Roover  J" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deroover J, Baro F, Bourguignon RP, Smets P</AU>
<TI>Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea</TI>
<SO>Curr Med Res Opin</SO>
<YR>1984</YR>
<VL>9</VL>
<NO>5</NO>
<PG>329-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goetz-CG" NAME="Goetz CG" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goetz CG, Tanner CM, Cohen JA, Thelen JA, Carroll VS, Klawans HL, et al</AU>
<TI>L-acetyl-carnitine in Huntington's disease: double-blind placebo controlled crossover study of drug effects on movement disorder and dementia</TI>
<SO>Mov Disord</SO>
<YR>1990</YR>
<VL>5</VL>
<NO>3</NO>
<PG>263-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hersch-G" NAME="Hersch G" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, et al</AU>
<TI>Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>2</NO>
<PG>250-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-INTRO_x002d_HD" NAME="INTRO-HD" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Huntington Study Group</AU>
<TI>Safety and tolerability of the free-radical scavenger OPC-14117 in Huntington's disease.</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>50</VL>
<PG>1366-1372</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kieburtz-K" NAME="Kieburtz K" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kieburtz K, Feigin A, McDermott M, Como P, Abwender D, Zimmerman C, et al</AU>
<TI>A controlled trial of remacemide hydrochloride in Huntington's disease</TI>
<SO>Mov Disord</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>3</NO>
<PG>273-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Mateo-D" MODIFIED="2009-04-26 15:22:45 +0100" MODIFIED_BY="[Empty name]" NAME="Mateo D" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mateo D, Gimenez-Roldan S</AU>
<TI>The effect of piracetam on involuntary movements in Huntington's disease. A double-blind, placebo-controlled study</TI>
<TO>El efecto del piracetam en los movimientos involuntarios en la enfermedad de Huntington</TO>
<SO>Neurologia</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>1</NO>
<PG>16-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-MINO" NAME="MINO" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Huntington study group</AU>
<TI>Minocycline safety and tolerability in Huntington disease</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63</VL>
<NO>3</NO>
<PG>547-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Miraxion_x002d_Europe" NAME="Miraxion-Europe" YEAR="20'07">
<REFERENCE NOTES="&lt;p&gt;oral communication&lt;/p&gt;" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<SO>World Congress in Huntington´s disease</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Murman-DL" NAME="Murman DL" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Murman DL, Giordani B, Mellow AM, Johanns JR, Little RJ, Hariharan M, et al</AU>
<TI>Cognitive, behavioral, and motor effects of the NMDA antagonist ketamine in Huntington's disease</TI>
<SO>Neurology</SO>
<YR>1997</YR>
<VL>49</VL>
<NO>1</NO>
<PG>153-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-O_x0027_Suilleabhain-P" MODIFIED="2008-08-25 13:53:34 +0100" MODIFIED_BY="[Empty name]" NAME="O'Suilleabhain P" YEAR="2003">
<REFERENCE MODIFIED="2008-08-25 13:53:34 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Suilleabhain P, Dewey RB, Jr</AU>
<TI>A randomized trial of amantadine in Huntington disease</TI>
<SO>Arch Neurol</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>7</NO>
<PG>996-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Quinn-N" NAME="Quinn N" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Quinn N, Marsden CD</AU>
<TI>A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia</TI>
<SO>J Neurol Neurosurg Psychiatry</SO>
<YR>1984</YR>
<VL>47</VL>
<NO>8</NO>
<PG>844-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RID_x002d_HD" NAME="RID-HD" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Huntington study group</AU>
<TI>Dosage effects of riluzole in Huntington's disease: a multicenter placebo-controlled study</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>61</VL>
<NO>11</NO>
<PG>1551-6.</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Roos-RA" NAME="Roos RA" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Roos RA, Buruma OJ, Bruyn GW, Kemp B, van der Velde EA</AU>
<TI>Tiapride in the treatment of Huntington's chorea</TI>
<SO>Acta Neurol Scand</SO>
<YR>1982</YR>
<VL>65</VL>
<NO>1</NO>
<PG>45-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stocchi-F" NAME="Stocchi F" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stocchi F, Carta A, Berardelli A, Antonini A, Argenta M, Formica A, et al</AU>
<TI>Effects of terguride in patients with Huntington's disease</TI>
<SO>Clin Neuropharmacol</SO>
<YR>1989</YR>
<VL>12</VL>
<NO>5</NO>
<PG>435-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-TETRA_x002d_HD" NAME="TETRA-HD" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>The Huntington study group</AU>
<TI>Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial</TI>
<SO>Neurology</SO>
<YR>2006</YR>
<VL>66</VL>
<NO>3</NO>
<PG>366-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-TREND_x002d_HD" NAME="TREND-HD" YEAR="2007">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>The Huntington Study group</AU>
<TI>TREND-HD - A Trial of Ethyl-EPA (Miraxion&#8482;) in Treating Mild to Moderate Huntington's Disease</TI>
<SO>World Congress in Huntington´s disease</SO>
<YR>2007</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Vaddadi-K" NAME="Vaddadi K" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vaddadi KS, Soosai E, Chiu E, Dingjan P</AU>
<TI>A randomised, placebo-controlled, double blind study of treatment of Huntington's disease with unsaturated fatty acids</TI>
<SO>Neuroreport</SO>
<YR>2002</YR>
<VL>13</VL>
<NO>1</NO>
<PG>29-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-van-Vugt-J" NAME="van Vugt J" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>van Vugt JP, Siesling S, Vergeer M, van der Velde EA, Roos RA</AU>
<TI>Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study</TI>
<SO>J Neurol Neurosurg Psychiatry</SO>
<YR>1997</YR>
<VL>63</VL>
<NO>1</NO>
<PG>35-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Verhagen-Metman-L" NAME="Verhagen Metman L" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, et al 12.</AU>
<TI>Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>5</NO>
<PG>694-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-12-04 05:04:26 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Albanese-A" MODIFIED="2008-08-25 12:58:04 +0100" MODIFIED_BY="[Empty name]" NAME="Albanese A" YEAR="1995">
<REFERENCE MODIFIED="2008-08-25 12:58:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albanese A, Cassetta E, Carretta D, Bentivoglio AR, Tonali P</AU>
<TI>Acute challenge with apomorphine in Huntington's disease: a double-blind study</TI>
<SO>Clin Neuropharmacol</SO>
<YR>1995</YR>
<VL>18</VL>
<NO>5</NO>
<PG>427-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Albano-C" NAME="Albano C" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Albano C, Cocito L</AU>
<TI>Huntington's chorea and bromocriptine</TI>
<SO>Arch Neurol</SO>
<YR>1979</YR>
<VL>36</VL>
<NO>5</NO>
<PG>322</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Alpay-M" MODIFIED="2008-11-18 16:38:01 +0000" MODIFIED_BY="[Empty name]" NAME="Alpay M" YEAR="2006">
<REFERENCE MODIFIED="2008-11-18 16:37:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Alpay M, Koroshetz WJ</AU>
<TI>Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease</TI>
<SO>Psychosomatics</SO>
<YR>2006</YR>
<VL>47</VL>
<NO>1</NO>
<PG>70 - 2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aminoff-MJ" NAME="Aminoff MJ" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aminoff MJ, Marshall J</AU>
<TI>Treatment of Huntington's chorea with lithium carbonate. A double-blind trial</TI>
<SO>Lancet</SO>
<YR>1974</YR>
<VL>1(7848)</VL>
<PG>107-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Asher-SW" NAME="Asher SW" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Asher SW, Aminoff MJ</AU>
<TI>Tetrabenazine and movement disorders</TI>
<SO>Neurology</SO>
<YR>1981</YR>
<VL>31(8)</VL>
<PG>1051-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Barr-AN" NAME="Barr AN" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Barr AN, Heinze W, Mendoza JE, Perlik S</AU>
<TI>Long term treatment of Huntington disease with L-glutamate and pyridoxine</TI>
<SO>Neurology</SO>
<YR>1978</YR>
<VL>28</VL>
<NO>12</NO>
<PG>1280-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bassi-S-_x0028_a_x0029_" NAME="Bassi S (a)" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bassi S, Albizzati MG, Corsini GU, Frattola L, Piolti R, Suchy I, Trabucchi M</AU>
<TI>Therapeutic experience with transdihydrolisuride in Huntington's disease</TI>
<SO>Neurology</SO>
<YR>1986</YR>
<VL>36(7)</VL>
<PG>984-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonelli-RM" NAME="Bonelli RM" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonelli RM, Mahnert FA, Niederwieser G</AU>
<TI>Olanzapine for Huntington's disease: an open label study</TI>
<SO>Clin Neuropharmacol</SO>
<YR>2002</YR>
<VL>25(5)</VL>
<PG>263-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bonuccelli-U" NAME="Bonuccelli U" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bonuccelli U, Ceravolo R, Maremmani C, Nuti A, Rossi G, Muratorio A</AU>
<TI>Clozapine in Huntington's chorea</TI>
<SO>Neurology</SO>
<YR>1994</YR>
<VL>44(5)</VL>
<PG>821-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Braun-A" NAME="Braun A" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braun A, Mouradian MM, Mohr E, Fabbrini G, Chase TN</AU>
<TI>Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders</TI>
<SO>J Neurol Neurosurg Psychiatry</SO>
<YR>1989</YR>
<VL>52(5)</VL>
<PG>631-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caine-ED" NAME="Caine ED" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caine ED, Polinsky RJ, Kartzinel R, Ebert MH</AU>
<TI>The trial use of clozapine for abnormal involuntary movement disorders</TI>
<SO>Am J Psychiatry</SO>
<YR>1979</YR>
<VL>136(3)</VL>
<PG>317-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caparros_x002d_Lefebvre-D" NAME="Caparros-Lefebvre D" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caparros-Lefebvre D, Dewailly D</AU>
<TI>[Preliminary pilot study of cyproterone acetate for the treatment of aggressive behavior associated with severe dementia]</TI>
<SO>Rev Neurol (Paris)</SO>
<YR>2005</YR>
<VL>161(11)</VL>
<PG>1071-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caraceni-TA-_x0028_a_x0029_" NAME="Caraceni TA (a)" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caraceni TA, Giovannini P, Girotti F, Avanzini G</AU>
<TI>Pharmacology of Huntington´s disease. Personal experience</TI>
<SO>Eur Neurol</SO>
<YR>1977</YR>
<VL>16</VL>
<NO>1-6</NO>
<PG>42-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caraceni-TA-_x0028_b_x0029_" MODIFIED="2008-11-12 00:57:14 +0000" MODIFIED_BY="[Empty name]" NAME="Caraceni TA (b)" YEAR="1978">
<REFERENCE MODIFIED="2008-11-12 00:57:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caraceni TA, Girotti F, Celano I, Parati E, Balboni L</AU>
<TI>2-Dymethylaminoethanol (Deanol) in Huntington´s chorea</TI>
<SO>Journal of Neurology, Neurosurgery and Psychiatry</SO>
<YR>1978</YR>
<VL>41</VL>
<PG>1114-1118</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caraceni-TA-_x0028_c_x0029_" NAME="Caraceni TA (c)" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caraceni TA, Girotti F, Giovannini P, Pederzoli M, Parati EA</AU>
<TI>Effects of DA agonist in Huntington disease hyperkinesia</TI>
<SO>Ital J Neurol Sci</SO>
<YR>1980</YR>
<VL>1</VL>
<NO>3</NO>
<PG>155-161</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carman-JS" NAME="Carman JS" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carman JS, Shoulson I, Chase TN</AU>
<TI>Huntington´s chorea treated with lithium carbonate</TI>
<SO>The Lancet</SO>
<YR>1974</YR>
<VL>1</VL>
<NO>7861</NO>
<PG>811</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Corsini-GU" NAME="Corsini GU" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Corsini GU, Onali P, Masala C, Cianchetti C, Mangoni A, Gessa G</AU>
<TI>Apomorphine hydrochloride-induced improvement in Huntington's chorea: stimulation of dopamine receptor</TI>
<SO>Arch Neurol</SO>
<YR>1978</YR>
<VL>35(1)</VL>
<PG>27-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dalby-M" NAME="Dalby M" YEAR="1969">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dalby MA</AU>
<TI>Effect of tetrabenazine on extrapyramidal movement disorders</TI>
<SO>Br Med J</SO>
<YR>1969</YR>
<VL>2</VL>
<NO>5654</NO>
<PG>422-423</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dallochio-C" NAME="Dallochio C" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dallocchio C, Buffa C, Tinelli C, Mazzarello P</AU>
<TI>Effectiveness of risperidone in Huntington chorea patients</TI>
<SO>J Clin Psychopharmacol</SO>
<YR>1999</YR>
<VL>19(1)</VL>
<PG>101-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Tommaso-_x0028_a_x0029_" NAME="de Tommaso (a)" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Tommaso M, Specchio N, Sciruicchio V, Difruscolo O, Specchio LM</AU>
<TI>Effects of rivastigmine on motor and cognitive impairment in Huntington's disease</TI>
<SO>Mov Disord</SO>
<YR>2004</YR>
<VL>19</VL>
<NO>12</NO>
<PG>1516-1518</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Tommaso-_x0028_b_x0029_" MODIFIED="2008-11-18 16:45:01 +0000" MODIFIED_BY="[Empty name]" NAME="de Tommaso (b)" YEAR="2005">
<REFERENCE MODIFIED="2008-11-18 16:45:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Tommaso M, Di Fruscolo O, Sciruicchio V, Specchio N, Cormio C, De Caro MF, Livrea P</AU>
<TI>Efficacy of levetiracetam in Huntington disease</TI>
<SO>Clin. Neuropharmacol</SO>
<YR>2005</YR>
<VL>28</VL>
<NO>6</NO>
<PG>280 - 4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Tommaso-_x0028_c_x0029_" MODIFIED="2008-11-18 16:45:15 +0000" MODIFIED_BY="[Empty name]" NAME="de Tommaso (c)" YEAR="2007">
<REFERENCE MODIFIED="2008-11-18 16:45:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Tommaso M, Difruscolo O, Sciruicchio V, Specchio N, Livrea P</AU>
<TI>Two years&#8217; follow-up of rivastigmine treatment in Huntington Disease</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>1</NO>
<PG>43-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dest_x00e9_e-A" NAME="Destée A" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Destée A, Petit H, Warot P</AU>
<TI>Effect of piracetam in Huntington's chorea</TI>
<SO>Eur Neurol</SO>
<YR>1984</YR>
<VL>23(2)</VL>
<PG>89-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dupont-E" NAME="Dupont E" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dupont E, Hansen AP, Juul-Jensen P, Lundbaek K, Magnussen I, de Fine Olivarius B</AU>
<TI>Somatostatin in the treatment of patients with extra-pyramidal disorders and patients with EEG abnormalities</TI>
<SO>Acta Neurol Scand</SO>
<YR>1978</YR>
<VL>57(6)</VL>
<PG>488-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernandez-HH" NAME="Fernandez HH" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez HH, Friedman JH, Grace J, Beason-Hazen S</AU>
<TI>Donepezil for Huntington's disease</TI>
<SO>Mov Disord</SO>
<YR>2000</YR>
<VL>15(1)</VL>
<PG>173-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fisher--R-_x0028_a_x0029_" NAME="Fisher  R (a)" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fisher R, Norris JW, Gilka L</AU>
<TI>Letter: G.A.B.A. in Huntington´s chorea</TI>
<SO>Lancet</SO>
<YR>1974</YR>
<VL>1</VL>
<NO>7856</NO>
<PG>506</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fisher-R-_x0028_b_x0029_" NAME="Fisher R (b)" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fisher R, Norris W, DeManuele F, Ridgley B, Malyon C</AU>
<TI>Huntington´s chorea</TI>
<SO>Can Med Assoc J</SO>
<YR>1982</YR>
<VL>126</VL>
<NO>6</NO>
<PG>605-606</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fog-R" NAME="Fog R" YEAR="1970">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fog R, Pakkenberg H</AU>
<TI>Combined nitoman-pimozide treatment of Huntington's chorea and other hyperkinetic syndromes</TI>
<SO>Acta Neurol Scand.</SO>
<YR>1970</YR>
<VL>46(2)</VL>
<PG>249-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Foster-NL" NAME="Foster NL" YEAR="1983">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Foster NL, Chase TN, Denaro A, Hare TA, Tamminga CA</AU>
<TI>THIP treatment of Huntington's disease</TI>
<SO>Neurology</SO>
<YR>1983</YR>
<VL>33(5)</VL>
<PG>637-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frattola-L-_x0028_a_x0029_" MODIFIED="2008-11-12 22:09:15 +0000" MODIFIED_BY="[Empty name]" NAME="Frattola L (a)" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frattola L, Albizzati MG, Alemani A, Bassi S, Ferrarese C, Trabucchi M</AU>
<TI>Acute treatment of Huntington's chorea with lisuride</TI>
<SO>J Neurol Sci</SO>
<YR>1983</YR>
<VL>59(2)</VL>
<PG>247-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Frattola-L-_x0028_b_x0029_" MODIFIED="2008-11-12 22:45:41 +0000" MODIFIED_BY="[Empty name]" NAME="Frattola L (b)" YEAR="1983">
<REFERENCE MODIFIED="2008-11-12 22:45:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Frattola L, Albizzati MG, Alemani A, Bassi S, Ferrarese C, Trabucchi M</AU>
<TI>Acute treatment of Huntington's chorea with lisuride</TI>
<SO>J Neurol Sci</SO>
<YR>1983</YR>
<VL>59</VL>
<NO>2</NO>
<PG>247-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gim_x00e9_nez_x002d_Rold_x00e1_n-S" MODIFIED="2008-11-12 22:09:35 +0000" MODIFIED_BY="[Empty name]" NAME="Giménez-Roldán S" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giménez-Roldán S, Mateo D</AU>
<TI>[Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements]</TI>
<SO>Neurologia</SO>
<YR>1989</YR>
<VL>4(8)</VL>
<PG>282-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Girke-W" NAME="Girke W" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Girke W, Lieske V</AU>
<TI>[Influence of the Benzodiazepine-derivative Ro 06-9098/000 on choreo-athetotic syndromes (author's transl)]</TI>
<SO>Pharmakopsychiatr Neuropsychopharmakol</SO>
<YR>1977</YR>
<VL>10(5)</VL>
<PG>281-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Girotti-F" NAME="Girotti F" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Girotti F, Carella F, Scigliano G, Grassi MP, Soliveri P, Giovannini P, Parati E, Caraceni T.</AU>
<TI>Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease</TI>
<SO>J Neurol Neurosurg Psychiatry</SO>
<YR>1984</YR>
<VL>47</VL>
<NO>8</NO>
<PG>848-852</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Giuffra-ME" MODIFIED="2008-08-20 13:01:15 +0100" MODIFIED_BY="[Empty name]" NAME="Giuffra ME" YEAR="1991">
<REFERENCE MODIFIED="2008-08-20 13:01:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Giuffra ME, Mouradian MM, Chase TN</AU>
<TI>Glutamatergic therapy of Huntington's chorea</TI>
<SO>Clin Neuropharmacol</SO>
<YR>1992</YR>
<VL>15</VL>
<NO>2</NO>
<PG>148-151</PG>
<IDENTIFIERS MODIFIED="2008-08-20 13:01:15 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gray-MW" NAME="Gray MW" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gray MW, Herzberg L, Lerman JA, Turnbull MJ, Victoratos G</AU>
<TI>Letter: Amantadine in chorea</TI>
<SO>Lancet</SO>
<YR>1975</YR>
<VL>2</VL>
<NO>7925</NO>
<PG>132-133</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Haslam-MT" NAME="Haslam MT" YEAR="1967">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Haslam MT</AU>
<TI>Cellular magnesium levels and the use of penicillamine in the treatment of Huntington's chorea</TI>
<SO>J Neurol Neurosurg Psychiatry</SO>
<YR>1967</YR>
<VL>30(2)</VL>
<PG>185-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Heckman-JM" NAME="Heckman JM" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heckmann JM, Legg P, Sklar D, Fine J, Bryer A, Kies B,</AU>
<TI>IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study</TI>
<SO>Neurology</SO>
<YR>2004</YR>
<VL>63(3)</VL>
<PG>597-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jankovic-J" NAME="Jankovic J" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jankovic J</AU>
<TI>Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study</TI>
<SO>Ann Neurol</SO>
<YR>1982</YR>
<VL>11(1)</VL>
<PG>41-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kartzinel-R" NAME="Kartzinel R" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kartzinel R, Hunt RD, Calne DB</AU>
<TI>Bromocriptine in Huntington chorea</TI>
<SO>Arch Neurol</SO>
<YR>1976</YR>
<VL>33(7)</VL>
<PG>517-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leng-TR" NAME="Leng TR" YEAR="2003">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leng TR, Woodward MJ, Stokes MJ, Swan AV, Wareing LA, Baker R.</AU>
<TI>Effects of multisensory stimulation in people with Huntington's disease: a randomized controlled pilot study.</TI>
<SO>Clin Rehabil</SO>
<YR>2003</YR>
<VL>17(1)</VL>
<PG>30-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Leonard-DP" NAME="Leonard DP" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Leonard DP, Kidson MA, Brown JG, Shannon PJ, Taryan S</AU>
<TI>A double blind trial of lithium carbonate and haloperidol in Huntington's chorea</TI>
<SO>Aust N Z J Psychiatry</SO>
<YR>1975</YR>
<VL>9(2)</VL>
<PG>115-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lucetti-C_x0028_a_x0029_" MODIFIED="2008-08-25 13:17:40 +0100" MODIFIED_BY="[Empty name]" NAME="Lucetti C(a)" YEAR="2002">
<REFERENCE MODIFIED="2008-08-25 13:17:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lucetti C, Gambaccini G, Bernardini S, Dell'Agnello G, Petrozzi L, Rossi G, Bonuccelli U</AU>
<TI>Amantadine in Huntington's disease: open-label video-blinded study</TI>
<SO>Neurol Sci</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>Suppl 2</NO>
<PG>S83-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lucetti-C_x0028_b_x0029_" MODIFIED="2008-08-25 13:17:27 +0100" MODIFIED_BY="[Empty name]" NAME="Lucetti C(b)" YEAR="2003">
<REFERENCE MODIFIED="2008-08-25 13:17:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lucetti C, Del Dotto P, Gambaccini G, Dell' Agnello G, Bernardini S, Rossi G, Murri L, Bonuccelli U</AU>
<TI>IV amantadine improves chorea in Huntington's disease: an acute randomized controlled study</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>12</NO>
<PG>1995-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Manyam-BV" NAME="Manyam BV" YEAR="1981">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Manyam BV, Katz L, Hare TA, Kaniefski K, Tremblay RD</AU>
<TI>Isoniazid-induced elevation of CSF GABA levels and effects on chorea in Huntington's disease</TI>
<SO>Ann Neurol</SO>
<YR>1981</YR>
<VL>10(1)</VL>
<PG>35-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mattson-B" MODIFIED="2008-12-04 05:04:26 +0000" MODIFIED_BY="[Empty name]" NAME="Mattson B" YEAR="1973">
<REFERENCE MODIFIED="2008-12-04 05:04:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mattsson B, Boman K</AU>
<TI>Letter: Buronil in Huntington's chorea</TI>
<SO>Lancet</SO>
<YR>1974</YR>
<VL>30</VL>
<NO>2</NO>
<PG>1323</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-McLellan-D" MODIFIED="2008-11-12 01:31:18 +0000" MODIFIED_BY="[Empty name]" NAME="McLellan D" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>McLellan DL, Chalmers RJ, Johnson RH</AU>
<TI>A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea</TI>
<SO>Lancet</SO>
<YR>1974</YR>
<VL>1(7848)</VL>
<PG>104-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nutt-JG-_x0028_a_x0029_" NAME="Nutt JG (a)" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nutt JG, Rosin A, Chase TN</AU>
<TI>Treatment of Huntington disease with a cholinergic agonist</TI>
<SO>Neurology</SO>
<YR>1978</YR>
<VL>28(10)</VL>
<PG>1061-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nutt-JG-_x0028_b_x0029_" MODIFIED="2008-11-12 01:41:49 +0000" MODIFIED_BY="[Empty name]" NAME="Nutt JG (b)" YEAR="1978">
<REFERENCE MODIFIED="2008-11-12 01:41:49 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nutt JG, Rosin AJ, Eisler T, Calne DB, Chase TN</AU>
<TI>Effect of an opiate antagonist on movement disorders</TI>
<SO>Arch Neurol</SO>
<YR>1978</YR>
<VL>35</VL>
<NO>12</NO>
<PG>810-811</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ondo-WG" NAME="Ondo WG" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ondo WG, Tintner R, Thomas M, Jankovic J</AU>
<TI>Tetrabenazine treatment for Huntington's disease-associated chorea</TI>
<SO>Clin Neuropharmacol</SO>
<YR>2002</YR>
<VL>25(6)</VL>
<PG>300-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pakkenberg-H" NAME="Pakkenberg H" YEAR="1968">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pakkenberg H</AU>
<TI>The effect of tetrabenazine in some hyperkinetic syndromes</TI>
<SO>Acta Neurol Scand</SO>
<YR>1968</YR>
<VL>44</VL>
<NO>3</NO>
<PG>391-393</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Paleacu-D" NAME="Paleacu D" YEAR="2002">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Paleacu D, Anca M, Giladi N.</AU>
<TI>Olanzapine in Huntington's disease</TI>
<SO>Acta Neurol Scand</SO>
<YR>2002</YR>
<VL>105</VL>
<NO>6</NO>
<PG>441-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pearce-I" MODIFIED="2008-11-12 01:44:57 +0000" MODIFIED_BY="[Empty name]" NAME="Pearce I" YEAR="1977">
<REFERENCE MODIFIED="2008-11-12 01:44:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pearce I, Heathfield KW, Pearce MJ</AU>
<TI>Valproate sodium in Huntington chorea</TI>
<SO>Arch Neurol</SO>
<YR>1977</YR>
<VL>34</VL>
<NO>5</NO>
<PG>308-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perry-TL-_x0028_a_x0029_" MODIFIED="2008-11-18 16:08:08 +0000" MODIFIED_BY="[Empty name]" NAME="Perry TL (a)" YEAR="1979">
<REFERENCE MODIFIED="2008-11-18 16:08:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perry TL, Wright JM, Hansen S, Thomas SM, Allan BM, Baird PA, Diewold PA</AU>
<TI>A double-blind clinical trial of isoniazid in Huntington disease</TI>
<SO>Neurology</SO>
<YR>1982</YR>
<VL>32(4)</VL>
<PG>354-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perry-TL-_x0028_b_x0029_" MODIFIED="2008-11-12 21:59:10 +0000" MODIFIED_BY="[Empty name]" NAME="Perry TL (b)" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perry TL, Wright JM, Hansen S, Allan BM, Baird PA, MacLeod PM</AU>
<TI>Failure of aminooxyacetic acid therapy in Huntington disease</TI>
<SO>Neurology.</SO>
<YR>1980</YR>
<VL>30(7 Pt 1)</VL>
<PG>772-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Perry-TL-_x0028_c_x0029_" MODIFIED="2008-11-18 16:09:00 +0000" MODIFIED_BY="[Empty name]" NAME="Perry TL (c)" YEAR="1982">
<REFERENCE MODIFIED="2008-11-18 16:09:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Perry TL, Wright JM, Hansen S</AU>
<TI>Isoniazid therapy in Huntington disease</TI>
<SO>Neurology</SO>
<YR>1979</YR>
<VL>29</VL>
<NO>3</NO>
<PG>370-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Piccinin-G" NAME="Piccinin G" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Piccinin G, Morocutti C, Urcioli R, Bernardi G</AU>
<TI>[Treatment of choreic syndromes with sodium dipropylacetate]</TI>
<SO>Riv Neurol</SO>
<YR>1977</YR>
<VL>47(2)</VL>
<PG>107-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saft-C-_x0028_a_x0029_" MODIFIED="2008-11-18 16:42:26 +0000" MODIFIED_BY="[Empty name]" NAME="Saft C (a)" YEAR="2005">
<REFERENCE MODIFIED="2008-11-18 16:42:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saft C, Andrich J, Kraus PH, Przuntek H</AU>
<TI>Amisulpride in Huntington's disease</TI>
<SO>Psychiatr Prax</SO>
<YR>2005</YR>
<VL>32</VL>
<NO>7</NO>
<PG>363 - 66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saft-C-_x0028_b_x0029_" MODIFIED="2008-11-18 16:42:44 +0000" MODIFIED_BY="[Empty name]" NAME="Saft C (b)" YEAR="2006">
<REFERENCE MODIFIED="2008-11-18 16:42:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saft C, Lauter T, Kraus PH, Przuntek H, Andrich J</AU>
<TI>Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series</TI>
<SO>BMC Neurol</SO>
<YR>2006</YR>
<VL>28;6</VL>
<PG>11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scigliano-G" NAME="Scigliano G" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scigliano G, Giovannini P, Girotti F, Grassi MP, Caraceni T, Schechter PJ</AU>
<TI>Gamma-vinyl GABA treatment of Huntington's disease</TI>
<SO>Neurology.</SO>
<YR>1984</YR>
<VL>34(1)</VL>
<PG>94-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Scotti-G" NAME="Scotti G" YEAR="1971">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Scotti G, Spinnler H</AU>
<TI>Amantadine and Huntington's chorea</TI>
<SO>N Engl J Med</SO>
<YR>1971</YR>
<VL>285(23)</VL>
<PG>1325-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Seppi-K" NAME="Seppi K" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Seppi K, Mueller J, Bodner T, Brandauer E, Benke T, Weirich-Schwaiger H, Poewe W, Wenning GK</AU>
<TI>Riluzole in Huntington's disease (HD): an open label study with one year follow-up</TI>
<SO>J Neurol</SO>
<YR>2001 J Neurol. 2001 Oct;248(10):866-9.</YR>
<VL>248(10)</VL>
<PG>866-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shoulson-I_x0028_a_x0029_" NAME="Shoulson I(a)" YEAR="1975">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shoulson I, Chase TN, Roberts E, Van Balgooy JN</AU>
<TI>Letter: Huntington's disease: treatment with imidazole-4-acetic acid</TI>
<SO>N Engl J Med</SO>
<YR>1975</YR>
<VL>293(10)</VL>
<PG>504-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shoulson-I_x0028_b_x0029_" NAME="Shoulson I(b)" YEAR="1978">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shoulson I, Goldblatt D, Charlton M, Joynt RJ</AU>
<TI>Huntington's disease: treatment with muscimol, a GABA-mimetic drug</TI>
<SO>Ann Neurol.</SO>
<YR>1978</YR>
<VL>4(3)</VL>
<PG>279-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Shults-C" MODIFIED="2008-11-12 05:34:10 +0000" MODIFIED_BY="[Empty name]" NAME="Shults C" YEAR="1986">
<REFERENCE MODIFIED="2008-11-12 05:34:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Shults C, Steardo L, Barone P, Mohr E, Juncos J, Serrati C, Fedio P, Tamminga CA, Chase TN</AU>
<TI>Huntington's disease: effect of cysteamine, a somatostatin-depleting agent</TI>
<SO>Neurology</SO>
<YR>1986</YR>
<VL>36(8)</VL>
<PG>1099-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Squittieri-F" NAME="Squittieri F" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Squitieri F, Cannella M, Piorcellini A, Brusa L, Simonelli M, Ruggieri S</AU>
<TI>Short-term effects of olanzapine in Huntington disease</TI>
<SO>Neuropsychiatry Neuropsychol Behav Neurol.</SO>
<YR>2001</YR>
<VL>14</VL>
<NO>1</NO>
<PG>69-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Swash-M" NAME="Swash M" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Swash M, Roberts AH, Zakko H, Heathfield KW</AU>
<TI>Treatment of involuntary movement disorders with tetrabenazine</TI>
<SO>J Neurol Neurosurg Psychiatry</SO>
<YR>1972</YR>
<VL>35(2)</VL>
<PG>186-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Symington-GR" MODIFIED="2008-11-12 22:02:48 +0000" MODIFIED_BY="[Empty name]" NAME="Symington GR" YEAR="1978">
<REFERENCE MODIFIED="2008-11-12 22:02:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Symington GR, Leonard DP, Shannon PJ, Vajda FJ</AU>
<TI>Sodium valproate in Huntington's disease</TI>
<SO>Am J Psychiatry</SO>
<YR>1978</YR>
<VL>135</VL>
<NO>3</NO>
<PG>352-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tarsy-D" NAME="Tarsy D" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tarsy D, Bralower M</AU>
<TI>Deanol acetamidobenzoate treatment in choreiform movement disorders</TI>
<SO>Arch Neurol</SO>
<YR>1977</YR>
<VL>34(12)</VL>
<PG>756-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tell-G" NAME="Tell G" YEAR="2001">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tell G, Böhlen P, Schechter PJ, Koch-Weser J, Agid Y, Bonnet AM, Coquillat G, Chazot G, Fischer C.</AU>
<TI>Treatment of Huntington disease with gamma-acetylenic GABA an irreversible inhibitor of GABA-transaminase: increased CSF GABA and homocarnosine without clinical amelioration</TI>
<SO>Neurology</SO>
<YR>1981</YR>
<VL>31(2)</VL>
<PG>207-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terrence-CF" NAME="Terrence CF" YEAR="1976">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terrence CF</AU>
<TI>Fluphenazine decanoate in the treatment of chorea: a double-blind study.Curr Ther Res Clin Exp. 1976 Aug;20(2):177-83.</TI>
<SO>Curr Ther Res Clin Exp</SO>
<YR>1976</YR>
<VL>20(2)</VL>
<PG>177-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tolosa-ES" NAME="Tolosa ES" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tolosa ES</AU>
<TI>Studies on the anti-dyskinesia effect of apomorphine in man</TI>
<SO>Neurol Neurocir Psiquiatr</SO>
<YR>1976</YR>
<VL>17(4)</VL>
<PG>223-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tourian-AY" NAME="Tourian AY" YEAR="1972">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tourian AY</AU>
<TI>Administration of 5-hydroxy-L-tryptophan to individuals with Huntington's chorea</TI>
<SO>Neurology</SO>
<YR>1972</YR>
<VL>22(11)</VL>
<PG>1201-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Van-Duijn-E" MODIFIED="2008-11-18 16:40:06 +0000" MODIFIED_BY="[Empty name]" NAME="Van Duijn E" YEAR="2005">
<REFERENCE MODIFIED="2008-11-18 16:40:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Van Duijn E, Roos RAC, Smarius LJCA, Van Der Mast RC</AU>
<TI>Electroconvulsive therapy in patients with Huntington's disease and depression</TI>
<SO>Ned Tijdschr Geneeskd</SO>
<YR>2005</YR>
<VL>149</VL>
<NO>39</NO>
<PG>2141 - 44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vestergaard-P" NAME="Vestergaard P" YEAR="1977">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vestergaard P, Baastrup PC, Petersson H</AU>
<TI>Lithium treatment of Huntington's chorea. A placebo-controlled clinical trial</TI>
<SO>Acta Psychiatr Scand</SO>
<YR>1977</YR>
<VL>56(3)</VL>
<PG>183-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Vitale-P" MODIFIED="2008-11-18 16:35:41 +0000" MODIFIED_BY="[Empty name]" NAME="Vitale P" YEAR="2007">
<REFERENCE MODIFIED="2008-11-18 16:35:36 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Vitale C, Marconi S, Di Maio L, De Michele G, Longo K, Bonavita V, Barone P</AU>
<TI>Short-term continuous infusion of apomorphine hydrochloride for treatment of Huntington's chorea: A double blind, randomized cross-over trial</TI>
<SO>Mov. Disord</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>16</NO>
<PG>2359 - 2364</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walker-FO" MODIFIED="2008-08-25 13:03:35 +0100" MODIFIED_BY="[Empty name]" NAME="Walker FO" YEAR="1989">
<REFERENCE MODIFIED="2008-08-25 13:03:35 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walker FO, Hunt VP</AU>
<TI>An open label trial of dextromethorphan in Huntington's disease</TI>
<SO>Clin Neuropharmacol</SO>
<YR>1989</YR>
<VL>12</VL>
<NO>4</NO>
<PG>322-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Worrall-EP" NAME="Worrall EP" YEAR="1974">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Worrall EP</AU>
<TI>Letter: Lithium in Huntington's chorea</TI>
<SO>Lancet</SO>
<YR>1974</YR>
<VL>2(7892)</VL>
<PG>1323</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zesiewicz-T" MODIFIED="2008-11-18 16:47:44 +0000" MODIFIED_BY="[Empty name]" NAME="Zesiewicz T" YEAR="2006">
<REFERENCE MODIFIED="2008-11-18 16:47:41 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zesiewicz, T, Sullivan KL, Hauser RA, Sanchez-Ramos J</AU>
<TI>Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease</TI>
<SO>Mov Disord</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>11</NO>
<PG>1998-2001</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zinzi-P" MODIFIED="2008-11-18 16:33:51 +0000" MODIFIED_BY="[Empty name]" NAME="Zinzi P" YEAR="2007">
<REFERENCE MODIFIED="2008-11-18 16:33:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zinzi P, Salmaso D, De Grandis R, Graziani G, Maceroni S, Bentivoglio A, Zappata P, Frontali M, Jacopini G</AU>
<TI>Effects of an intensive rehabilitation programme on patients with Huntington's disease: A pilot study</TI>
<SO>Clin. Rehabil</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>7</NO>
<PG>603 - 613</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-04-11 22:48:58 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-Curtis-A" MODIFIED="2008-08-25 12:23:19 +0100" MODIFIED_BY="[Empty name]" NAME="Curtis A" YEAR="2007">
<REFERENCE MODIFIED="2008-08-25 12:23:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Curtis A</AU>
<SO>World Congress of Huntington´s disease</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-DIMOND_x002d_A" MODIFIED="2008-08-25 12:51:49 +0100" MODIFIED_BY="[Empty name]" NAME="DIMOND-A" YEAR="2007">
<IDENTIFIERS MODIFIED="2008-08-25 12:51:49 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-25 12:26:52 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00387270"/>
<IDENTIFIER MODIFIED="2008-08-25 12:51:49 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="A Multicenter, Phase 1-2A, Open-Label, Dosage-Escalation and Randomized, Double-Blinded, Placebo-Controlled Study of Dimebon in Subjects With Huntington's Disease"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-PHEND_x002d_HD" MODIFIED="2008-08-25 12:57:11 +0100" MODIFIED_BY="[Empty name]" NAME="PHEND-HD" YEAR="2006">
<IDENTIFIERS MODIFIED="2008-08-25 12:57:09 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-25 12:27:33 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00212316"/>
<IDENTIFIER MODIFIED="2008-08-25 12:57:09 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="Phenylbutyrate Development for Huntington's Disease (PHEND-HD): A Multi-Center, Double-Blind, Placebo-Controlled Study With Open-Label Follow-Up to Determine the Safety and Tolerability of Phenylbutyrate in Subjects With Huntington's Disease"/>
</IDENTIFIERS>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES MODIFIED="2009-04-11 22:48:58 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Atomoxetine" MODIFIED="2009-04-11 22:48:58 +0100" MODIFIED_BY="[Empty name]" NAME="Atomoxetine" YEAR="2008">
<IDENTIFIERS>
<IDENTIFIER TYPE="CTG" VALUE="NCT00368849"/>
<IDENTIFIER TYPE="OTHER" VALUE="Atomoxetine for Attention Deficits in Adults With Mild HD: A Randomized, Placebo-Controlled Crossover Study"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-CIT_x002d_HD" MODIFIED="2008-11-12 00:42:20 +0000" MODIFIED_BY="[Empty name]" NAME="CIT-HD" YEAR="2005">
<IDENTIFIERS MODIFIED="2008-11-12 00:42:20 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-12 00:42:20 +0000" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00271596"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Memantine" MODIFIED="2008-08-25 12:31:18 +0100" MODIFIED_BY="[Empty name]" NAME="Memantine" YEAR="2007">
<IDENTIFIERS MODIFIED="2008-08-25 12:31:18 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-08-25 12:31:18 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00652457"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-11-08 06:16:25 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-11-08 06:16:25 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bonneli-RM-2005" NAME="Bonneli RM 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bonneli RM, Hofmann P</AU>
<TI>Pharmacological management of Huntington´s disease: an evidence-based review</TI>
<SO>Current Pharmaceutical Design</SO>
<YR>2005</YR>
<VL>12</VL>
<NO>21</NO>
<PG>2701-2720</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cochrane-2008" MODIFIED="2008-11-08 06:13:40 +0000" MODIFIED_BY="[Empty name]" NAME="Cochrane 2008" TYPE="OTHER">
<SO>www.cochrane.org/resources/handbook/</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EHDN-2007" NAME="EHDN 2007" TYPE="JOURNAL_ARTICLE">
<AU>European Huntington Disease Initiative Study Group</AU>
<TI>Riluzole in Huntington´s disease: a 3 year, randomised controlled study</TI>
<SO>Annals of Neurology</SO>
<YR>2007</YR>
<VL>62(3)</VL>
<PG>262-272</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-HSG-1996" MODIFIED="2008-11-08 03:40:14 +0000" MODIFIED_BY="[Empty name]" NAME="HSG 1996" TYPE="JOURNAL_ARTICLE">
<AU>Huntington Study Group</AU>
<TI>Unified Huntington's disease rating scale: Reliability and consistency</TI>
<SO>Movement Disorders</SO>
<YR>1996</YR>
<VL>11</VL>
<NO>2</NO>
<PG>136-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/mds.870110204"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jadad-1996" NAME="Jadad 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ</AU>
<TI>Assessing the quality of reports of randomized clinical trials: is blinding</TI>
<SO>Control Clin Trials</SO>
<YR>1996</YR>
<VL>17</VL>
<NO>1</NO>
<PG>1-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kieburtz-1994" NAME="Kieburtz 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kieburtz, K et al</AU>
<TI>Trinucleotide repeat length and progression of illness in Huntington's disease</TI>
<SO>J Med Genet</SO>
<YR>1994</YR>
<VL>31(11)</VL>
<PG>872-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lanska-1995" NAME="Lanska 1995" TYPE="JOURNAL_ARTICLE">
<AU>Lanska, DJ</AU>
<TI>George Huntington and hereditary chorea</TI>
<SO>J Child Neurol</SO>
<YR>1995</YR>
<VL>10(1)</VL>
<PG>46-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Revman-2008" MODIFIED="2008-11-08 06:16:25 +0000" MODIFIED_BY="[Empty name]" NAME="Revman 2008" TYPE="OTHER">
<AU>Review Manager (RevMan) [MacOSX]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008</AU>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ropper-2005" MODIFIED="2008-08-20 13:05:37 +0100" MODIFIED_BY="[Empty name]" NAME="Ropper 2005" TYPE="BOOK">
<AU>Ropper AH, Brown RH</AU>
<SO>Principles of Neurology</SO>
<YR>2005</YR>
<EN>8th</EN>
<PB>McGraw-Hill</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-TH-s-DCR-Group-1993" NAME="TH s DCR Group 1993" TYPE="JOURNAL_ARTICLE">
<AU>Group, THsDCR</AU>
<TI>A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosome</TI>
<SO>Cell</SO>
<YR>1993</YR>
<VL>72</VL>
<PG>971-983</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-04-26 15:25:56 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-04-26 15:25:56 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-04-26 14:05:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Como-PG">
<CHAR_METHODS MODIFIED="2009-04-10 20:28:37 +0100" MODIFIED_BY="[Empty name]">
<P>16-week double-blind, parallel study. Method of randomisation: computer-generated blocking and stratification.<BR/>Results presented for each arm of the study.<BR/>Per-protocol data analysis.<BR/>Location: 2 centres (USA).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-10 20:44:35 +0100" MODIFIED_BY="[Empty name]">
<P>30 patients, 7 drop-outs. 18 male and 12 female patients.<BR/>Mean age of participants: 43.6 ±11.9 years. Mean disease duration: 6.2±4.3 years.<BR/>Inclusion criteria: HD (nondepressed and ambulatory),TFC-UHDRS between 3-13.<BR/>Exclusion criteria: antidepressant medication, Hamilton Depression Inventory&#8805;20, MMSE&#8804;24</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-26 14:05:30 +0100" MODIFIED_BY="[Empty name]">
<P>Oral fluoxetine 20 mg/day (17 patients) and matching placebo (13 patients). Possible titration to fluoxetine 20 mg twice a day (not done).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-10 20:48:31 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: functional capacity (TFC-UHDRS).</P>
<P>Secondary:</P>
<UL>
<LI>Motor signs by a standardized motor scale: (chorea, dystonia, bradykinesia, oculomotor movements, cerebellar function).</LI>
<LI>Cognitive examination (Selective Reminding test, Visual Memory test, Controlled Oral Word Association test, Design Fluency test, Trail making test, Stroop Interference test, Digit Symbol test, MMSE).</LI>
<LI>Psychiatric examination (Hamilton Depression Inventory, Zung Anxiety scale, Leyton Obsessional Inventory, Hopkins Symptom Checklist Revised, Cognitive Behavior Rating Scale, Independency scale).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Negative for efficacy measures</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 14:06:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Consroe-P">
<CHAR_METHODS MODIFIED="2009-04-10 20:29:53 +0100" MODIFIED_BY="[Empty name]">
<P>15-week double-blind, cross-over study. Washout periods: 2 weeks pre-trial and 1 week in-between blocks. Method of randomisation: not described.<BR/>Results presented as combined data from treatment and placebo periods.<BR/>Per-protocol data analysis.<BR/>Location: 1 centre (USA).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>18 patients, 3 drop-outs. 11 male and 7 female patients.<BR/>Mean age of participants: 47.8 ±15.3 years.<BR/>Mean disease duration: 5.0±2.8 years. <BR/>Inclusion criteria: HD (clinical diagnosis and positive family history), mild or moderate progression (HD stage 1-4), cooperative, lucid and ambulatory, adequate third-party support.<BR/>Exclusion criteria: active or progressive hematologic, renal, hepatic, endocrine, cardiac or pulmonary disease; neuroleptics (obligatory pre-trial 2 week wash-out period), child-bearing age, pregnant, fertile women, no contraception.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral Cannabidiol 10 mg/kg/day. No titration.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-26 14:06:07 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: change in chorea severityt (Marsden and Quinn scale).</P>
<P>Secondary:</P>
<UL>
<LI>Cannabis side effects (cannabis side effect inventory, blood pressure, weight, clinical laboratorial tests, cannabidiol blood level)</LI>
<LI>Functional capacity (Shoulson and Fahn functional disability scale and HD staging system).</LI>
<LI>Motor and cognitive function (tongue extension test, finger tapping test, screw-and-nut test, Buschke-Fuld selective reminding tasks).</LI>
<LI>Psychological distress (SLC-90R).</LI>
</UL>
<UL>
<LI>Physician´s and patients´ assessment of treatment effect.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-10 20:37:23 +0100" MODIFIED_BY="[Empty name]">
<P>Negative for efficacy measures.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 14:29:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Cubo-E">
<CHAR_METHODS MODIFIED="2009-04-10 20:37:25 +0100" MODIFIED_BY="[Empty name]">
<P>12-week double-blind, parallel study (follow-up: 12 weeks). Method of randomisation: random-length permuted blocking.</P>
<P>Results presented for each arm of the study.<BR/>Per-protocol data analysis.<BR/>Location: 1 centre (USA).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-10 20:32:44 +0100" MODIFIED_BY="[Empty name]">
<P>30 patients, 6 drop-outs. 14 male and 16 female patients.<BR/>Mean age of participants: 46.6 ± 9.8 years.<BR/>Mean disease duration: 4.7 ± 4.2 years.<BR/>Inclusion criteria: adult, positive genetic test for HD or a positive family history of chorea and psychiatric disorder, UHDRS-chorea score minimum of 6.<BR/>Exclusion criteria: pregnancy or breastfeeding, sensitivity to donepezil, Hamilton Disease Rating scale score for depression of &#8805;15, history of stereotaxic brain surgery for HD, use of cholinergic/anticholinergic/antidopaminergic drugs within 4 weeks before enrollment. Dementia according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and MMSE&lt;24.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-08 05:35:16 +0000" MODIFIED_BY="[Empty name]">
<P>Oral donepezil 10 mg/day (15 patients) and placebo (identical in appearance, 15 patients). Titration 5 mg/day in the first 6 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-26 14:29:04 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: change in chorea (UHDRS-motor, chorea item).</P>
<P>Secondary:</P>
<UL>
<LI>Change in cognition (UHDRS cognitive, cognitive portion of the Alzheimer Disease Assessment Scale, WAIS III symbol searching raw score).</LI>
<LI>Change in functional status (UHDRS functional assessment).</LI>
<LI>Change in quality of life (Sickness Impact Profile scale).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-10 20:37:39 +0100" MODIFIED_BY="[Empty name]">
<P>Negative for primary outcome measure.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 15:25:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Roover--J">
<CHAR_METHODS MODIFIED="2009-04-10 20:34:06 +0100" MODIFIED_BY="[Empty name]">
<P>9-week double-blind, cross-over study. Washout periods: 1 week pre-trial, no period between blocks. Method of randomisation: not described.<BR/>Results presented as combined data from treatment and placebo periods.<BR/>Per-protocol data analysis.<BR/>Location: 1 centre (Belgium).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-26 15:25:56 +0100" MODIFIED_BY="[Empty name]">
<P>29 patients, 6 drop-outs. 11 male and 12 female patients (per-protocol cohort).<BR/>Mean age of participants: 44.8 years (per-protocol cohort).<BR/>Mean disease duration: 2.3 years (per-protocol cohort).<BR/>Inclusion criteria: HD (clinical diagnosis and positive family history), stage II/III of Shoulson and Fahn functional scale, &lt; 60 years.<BR/>Exclusion criteria:other neurological or psychiatric disease, alcoholism, poor physical condition. Any condition liable to cause sedation or interfere with symptom evaluation. Allowed medication: anxiolytics and antidepressives, except for inhibitors of monoamino oxidase.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral Tiapride 3 g/day, no titration.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-10 20:34:46 +0100" MODIFIED_BY="[Empty name]">
<P>Change in chorea grade (4-point severity scale).<BR/>Change in motor skills (5-point severity scale).<BR/>Wakefulness and motor performance (Leeds Psychomotor Tester).<BR/>Anxiety, irritability and unsociability (subjective patient assessment).<BR/>Depression (Zung self-rating scale).<BR/>Blood pressure and side-effects.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-26 14:33:12 +0100" MODIFIED_BY="[Empty name]">
<P>Chorea grade (head, p=0.00; trunk , p=0.05; upper limbs, p=0.01; lower limbs, p=0.01) and 3 out of 7 motor skills markedly improved (putting on and taking off socks, p=0-00; drinking from glass, p=0.00; pouring water from a bottle into a glass, p=0.01).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 14:33:21 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Goetz-CG">
<CHAR_METHODS MODIFIED="2009-04-26 14:33:21 +0100" MODIFIED_BY="[Empty name]">
<P>4-week double-blind, cross-over study. Washout periods: 2 weeks in-between blocks. Method of randomisation: not described.<BR/>Results presented as combined data from treatment and placebo periods.<BR/>Intention to treat data analysis.<BR/>Location: 1 centre (USA).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-10 20:36:55 +0100" MODIFIED_BY="[Empty name]">
<P>10 patients, no drop-outs. 4 male and 6 female patients.<BR/>Mean age of participants: 51.6±16.7 years.<BR/>Mean disease duration: 6.3±3.6 years.<BR/>Inclusion criteria: chorea, dementia and positive family history.<BR/>Exclusion criteria: concomitant medication in unconstant dosage.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral L-acetyl-carnitine 45 mg/kg/day, no titration.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-10 20:36:46 +0100" MODIFIED_BY="[Empty name]">
<P>Disability (Shoulson-Fahn Disability scale).<BR/>Abnormal movements (AIMS, reaction time).<BR/>Dementia (MMSE, Controlled Oral World Association test).<BR/>Depression (Hamilton depression scale).<BR/>Global severity assessment (AIMS).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-10 20:38:10 +0100" MODIFIED_BY="[Empty name]">
<P>Negative for efficacy measures.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-10 20:48:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hersch-G">
<CHAR_METHODS MODIFIED="2009-04-10 20:38:13 +0100" MODIFIED_BY="[Empty name]">
<P>16-week double-blind, parallel study (follow-up: 24 weeks). Method of randomisation: computer generated blocking and stratification by site.</P>
<P>Results presented for each arm of the study.<BR/>Intention-to-treat data analysis.<BR/>Location: 10 centres (USA).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-10 20:38:30 +0100" MODIFIED_BY="[Empty name]">
<P>64 patients, 5 drop-outs. 38 male and 26 female patients.<BR/>Mean age of participants: 46.3 years.<BR/>Mean disease duration: 7.0 ± 4.5 years.<BR/>Inclusion criteria: adult, genetically established HD, TFC-UHDRS&#8805;5, caregiver to witness consent and monitor compliance.<BR/>Exclusion criteria: creatine exposure in&lt;30 days; hematological, renal or hepatic disease, leu&lt;3800/mm3; creatinine&gt;2 mg/dL, ALT &gt;2xnormal, unstable psychiatric or medical conditions.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral creatine 8 mg/day (32 patients) and placebo (32 patients). No titration.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-10 20:48:14 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: tolerability (rate of treatment failures: non completion of study, drug suspension&gt;1, more than 1 week of drug suspension).</P>
<P>Secondary:</P>
<UL>
<LI>UHDRS motor, cognitive, behavioral and functional scales.</LI>
<LI>8OH2'dG concentration (plasma).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Safe but no effect on UHDRS scales.<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 14:39:43 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-INTRO_x002d_HD">
<CHAR_METHODS MODIFIED="2009-04-26 14:38:56 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_PARTICIPANTS MODIFIED="2009-04-26 14:38:56 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_INTERVENTIONS MODIFIED="2009-04-26 14:38:56 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_OUTCOMES MODIFIED="2009-04-26 14:39:43 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: tolerability (proportion of patients that completed the first 12 weeks of the trial).</P>
<P>Secondary:</P>
<UL>
<LI>Tolerability (number and severity of adverse events, number of withdrawals) and safety (changes in vital signs and laboratory tests).</LI>
<LI>Efficacy [change in UHDRS-total; UHDRS-subitems; neuropsychological test - trail making A and B, Hopkins Verbal Learning test, Digit Span, Digit Ordering task, Conditional Associative Learning task, Mental Rotation Test, Brief test of Attention, Personality (Frontal lobe Personality Scale), mood (Beck Depression Inventory)].</LI>
<LI>Free-radical assays (CSF and plasma).</LI>
<LI>OPC-14117 concentration (CSF and plasma).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-10 20:38:59 +0100" MODIFIED_BY="[Empty name]">
<P>Negative for efficacy measures.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 14:40:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kieburtz-K">
<CHAR_METHODS MODIFIED="2009-04-26 14:40:02 +0100" MODIFIED_BY="[Empty name]">
<P>6-week double-blind, three-arm parallel study. Method of randomisation: not described.<BR/>Results presented for each arm of the study.<BR/>Intention-to-treat data analysis.<BR/>Location: 1 centre (USA).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-26 14:40:23 +0100" MODIFIED_BY="[Empty name]">
<P>31 patients, 2 drop-outs. 18 male and 13 female patients.<BR/>Median age of participants: 48.0 ± 12.2 years.<BR/>Median disease duration: 9.6 ± 4.2 years.<BR/>Inclusion criteria: genetically established HD.<BR/>Exclusion criteria: another neurological illness or injury, poorly controlled epilepsy, end-stage HD (dementia, spasticity, need of continuous care), insulin-dependent diabetes mellitus, major psychiatric disorder without stable antidepressant or antipsychotic medication for &#8805; 6 months, high dose of antioxidants (vitamin E).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral remacemide 200 mg/day (10 patients) or 600 mg /day (10 patients) or placebo (11 patients). No titration.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-26 14:40:38 +0100" MODIFIED_BY="[Empty name]">
<P>1. Safety/tolerability (proportion of patients that completed the trial resulting from noncompliance and development of moderate or severe adverse events)<BR/>2. Number and severity of adverse events, occurrence of laboratory abnormalities.<BR/>3. Change in functional capacity (HDFCS).<BR/>4. Change in chorea grade (HDMRS).<BR/>5. Neuropsychological performance (MMSE, Trail making A and B, Symbol Digit test, Stroop Interference test, three immediate-recall trials of Hopkins Verbal Learning Test, Beck Depression Inventory).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Safe but negative for efficacy measures<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-10 20:46:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mateo-D">
<CHAR_METHODS MODIFIED="2009-04-10 20:46:41 +0100" MODIFIED_BY="[Empty name]">
<P>Double 30 minute-infusion with a follow-up of 4 hours in a double-blind, cross-over study. Washout periods: 2 weeks between trials. Method of randomisation: not described.<BR/>Results presented as combined data from treatment and placebo periods.<BR/>Intention-to-treat data analysis.<BR/>Location: 1 centre (Spain).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-10 20:45:54 +0100" MODIFIED_BY="[Empty name]">
<P>11 patients, no drop-outs. 6 male and 5 female patients.<BR/>Mean age of participants: 47.2±10.5 years.<BR/>Mean disease duration: 8.9±5.1 years.<BR/>Inclusion criteria: not described.<BR/>Exclusion criteria: not described.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Endovenous piracetam 12 g per administration.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-10 20:46:03 +0100" MODIFIED_BY="[Empty name]">
<P>Involuntary movements (Kartzinel, Hunt, Calne scale).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-10 20:45:58 +0100" MODIFIED_BY="[Empty name]">
<P>Worsening of involuntary movements at 4 hours post-infusion (p&lt;0.05).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 14:42:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-MINO">
<CHAR_METHODS>
<P>8-week (follow-up:1 week) double-blind, parallel study. Method of randomisation: computer generated blocking and stratification by site. <BR/>Results presented for each arm of the study. <BR/>Intention-to-treat data analysis.<BR/>Location: 8 centres (USA and Canada).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-10 21:15:32 +0100" MODIFIED_BY="[Empty name]">
<P>60 patients, 6 drop-outs. 31 male and 29 female patients.<BR/>Mean age of participants: 46.0±9.1 years.<BR/>Mean disease duration: 6.7±4.2 years.<BR/>Inclusion criteria: confirmed HD (not otherwise specified), &gt;18 years, TFC-UHDRS&gt;5, caregiver to informed consent and to oversee study medication.<BR/>Exclusion criteria: history of minocycline intolerability, WBC&lt;3800/mm3, creatinine &gt;2,0 mg/dL, ALT&gt;2xULN, unstable medical or psychiatric illness, history of systemic lupus erythematous, anti-nuclear antibodies&gt;1:40.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral minocycline 100 or 200 mg/day (18 and 19 patients in each arm, respectively); placebo (matching placebo; 23 patients). No titration.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-10 20:49:54 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: tolerability (failure to complete 8 weeks on assigned treatment or more than 1 allowable drug suspension).<BR/>Secondary: UHDRS (motor, cognitive, behavioral, functional).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-26 14:42:30 +0100" MODIFIED_BY="[Empty name]">
<P>Safe and tolerated. Treatment assignment did not affected study completion.</P>
<P>Treatment group performed worse in the Stroop interference test: 1.87 ± 4.83 placebo group vs. 1.50 ± 6.68; Minocycline 100 mg/day vs. -3.42 ± 10.5; Minocycline 200 mg/day; p = 0.04.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 14:44:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Miraxion_x002d_Europe">
<CHAR_METHODS MODIFIED="2009-04-10 20:50:40 +0100" MODIFIED_BY="[Empty name]">
<P>32-week double-blind, placebo controlled, parallel study.<BR/>Method of randomisation: computer generated blocking.<BR/>Results presented for each arm of the study.<BR/>Modified intention-to-treat data analysis (randomised and at least one post-baseline efficacy assessment).<BR/>Location: 27 centres (Europe).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-26 14:44:20 +0100" MODIFIED_BY="[Empty name]">
<P>290 patients.<BR/>Inclusion Criteria: &gt;35 years, clinical HD and confirmatory family history of HD, and/or genetic diagnosis.<BR/>Ambulatory, not requiring skilled nursing care (TFC-UHDRS&gt;7), chorea score(UHDRS)&gt;2 in one extremity. Maximal dystonia &#8804;2 and maximal bradykinesia &#8804;2. Stable dosages of non competitive NMDA receptor antagonists, and/or antiepileptic medications for 60 days prior to baseline. Females of child-bearing potential must use adequate birth control.<BR/>Exclusion Criteria: history of established diagnosis of tardive dyskinesia, clinical evidence of unstable medical or psychiatric illness, clinically significant active and unstable psychotic disease (hallucinations or delusions). Major depression (Beck Depression Inventory [BDI]-II Score &gt;20) at Screening Visit. Suicidal ideation (BDI-II item 9 &#8805; 2) at Screening Visit. History of clinically significant substance abuse within 12 months of Baseline Visit. Pregnant/lactating women. Participation in other drug studies within 60 days prior to Baseline Visit. Previous participation in any investigational study of ethyl-EPA (Miraxion&#8482;). Use of aspirin at daily dosage greater than 325 mg/day. Exclusionary Drugs (within 6 months of Baseline Visit): depot neuroleptics. Exclusionary Drugs (within 60 days of Baseline Visit): omega-3 supplementation, tetrabenazine or reserpine, high dose and/or variable dose oral anti-psychotic medications, steroid (other than topical), selenium supplements &gt; 55 mcg/day, lithium, benzodiazepines (except for low dose), anticoagulants.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral ethyl-EPA 2 g/day (147 patients) and placebo (143 patients). No titration.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-10 20:50:30 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: effect on TMS-4 (UHDRS) at 6 months.<BR/>Secondary:</P>
<UL>
<LI>Chorea (UHDRS).</LI>
<LI>TMS (UHDRS).</LI>
<LI>Clinical Global Impression (CGI-UHDRS).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-10 20:50:34 +0100" MODIFIED_BY="[Empty name]">
<P>Negative for efficacy measures.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 14:47:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Murman-DL">
<CHAR_METHODS MODIFIED="2009-04-10 20:53:49 +0100" MODIFIED_BY="[Empty name]">
<P>1-week double-blind, cross-over study. Washout period: 1 week in-between testing days. Method of randomisation: not described.<BR/>Results presented as combined data for each dosage in the treatment and placebo periods.<BR/>Data analysis: unclear.<BR/>Location: 1 centre (USA).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-10 20:54:56 +0100" MODIFIED_BY="[Empty name]">
<P>10 patients, 0 drop-outs. 4 male and 6 female patients.<BR/>Mean age of participants:48.4±12.8 years.<BR/>Mean disease duration: 4.7±3.9 years.<BR/>Inclusion criteria: autosomal-dominant, neurodegenerative disease and adequate clinical characteristics; no alternative explanation for the neurologic signs.<BR/>Exclusion criteria: CNS medication (antidepressant, antipsychotic), pregnancy, conditions that increase the exposure risk to ketamine or alter pharmacokinetics, Buschke Selective Reminding Test &gt;5/10 in at least 1 of 6 trials.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Endovenous ketamine: escalating dosage of 0.1, 0.4 and 0.6 mg/kg/hr.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-26 14:47:24 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: cognitive function (<U>verba</U>
<B>l</B> - Buschke Selective Reminding Test; <U>visual memory </U>- Washington Square Picture Memory test; <U>verbal fluency</U>; <U>attention</U> - digit span forward; <U>simple reaction time</U>; <U>psychomotor skills</U> - finger tapping).<BR/>Secondary:</P>
<UL>
<LI>Motor signs (UHDRS - items 7 to 17).</LI>
<LI>Psychiatric and physical symptoms (Institute of Mental Health Self Rating Scale and Brief Psychiatric Rating Scale).</LI>
<LI>Ketamine blood levels.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-10 20:53:58 +0100" MODIFIED_BY="[Empty name]">
<P>Negative for efficacy measures. Declines in verbal and fluency memory (immediate recall in Buschke Selective Reminding Test), immediate and delayed recall (Washington Square Picture Memory test) and in Verbal Fluency test.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 14:47:52 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Suilleabhain-P">
<CHAR_METHODS MODIFIED="2009-04-26 14:47:39 +0100" MODIFIED_BY="[Empty name]">
<P>4-week double-blind, cross-over study. No washout periods. Method of randomisation: not described.<BR/>Results presented as combined data from treatment and placebo periods.<BR/>Per-protocol data analysis.<BR/>Location: 1 centre (USA).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-26 14:47:52 +0100" MODIFIED_BY="[Empty name]">
<P>25 patients, 1 drop-out. 10 male and 14 female patients.<BR/>Mean age of participants: 51±13 years.<BR/>Mean disease duration: 6 years.<BR/>Inclusion criteria: clinical definite or a genetic diagnosis of HD, &gt;18 years, chorea at screening, MMSE&gt;20.<BR/>Exclusion criteria: severe psychosis and depression (symptoms of paranoia, hallucinations, suicidal).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral amantadine 300 mg/day. No titration.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-10 20:56:12 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: change in maximal chorea grade (24-point scale).</P>
<P>Secondary:</P>
<UL>
<LI>Change in chorea grade questionnaire (patient view).</LI>
<LI>Number of errors in a proprioception task.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-10 20:55:17 +0100" MODIFIED_BY="[Empty name]">
<P>Negative for primary outcome measure.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 14:48:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Quinn-N">
<CHAR_METHODS MODIFIED="2009-04-10 20:58:17 +0100" MODIFIED_BY="[Empty name]">
<P>9-week double-blind, cross-over study. Washout periods: 2 weeks pre-trial; 1 week in-between blocks. Method of randomisation: not described.<BR/>Results presented individually for each patient.<BR/>Per-protocol data analysis.<BR/>Location: 1 centre (UK).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-10 20:57:42 +0100" MODIFIED_BY="[Empty name]">
<P>11 patients, 1 drop-out , 7 male and 4 female patients.<BR/>Mean age of participants: 53.0 years.<BR/>Mean disease duration: 6.7 years.<BR/>Inclusion criteria: HD (not otherwise specified).<BR/>Exclusion criteria: use of neuroleptics in preceding 2 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-26 14:48:35 +0100" MODIFIED_BY="[Empty name]">
<P>Oral Sulpiride 300-1200 mg/day. Titration 300 mg in each week (mean dosage: 1054 mg/day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-26 14:48:39 +0100" MODIFIED_BY="[Empty name]">
<P>Reduction in dyskinesia (movement count, a combined score for abnormal movements).<BR/>Functional capacity.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-10 20:57:45 +0100" MODIFIED_BY="[Empty name]">
<P>Improvement in median movement count (38 -placebo- vs 14 -sulpiride - ; p&lt;0.01) and chorea severity score (33 -placebo- vs 29 -sulpiride-; p&lt;0.01).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 14:50:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-RID_x002d_HD">
<CHAR_METHODS>
<P>8-week double-blind, three-arm parallel study. Method of randomisation: computer generated blocking and stratification.<BR/>Results presented for each arm of the study.<BR/>Intention-to-treat data analysis.<BR/>Location: 9 centres (USA and Canada).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-26 14:50:13 +0100" MODIFIED_BY="[Empty name]">
<P>63 patients, 7 drop-outs. 31 male and 32 female patients.<BR/>Mean age of participants: 47.4±9.1 years.<BR/>Mean disease duration: 5.5±3.5 years.<BR/>Inclusion criteria:confirmed HD by family history and CAG&#8805;37 repeats, TFC-UHDRS&#8805;7, caregiver to witness consent and medication compliance.<BR/>Exclusion criteria: intolerability to riluzole, exposure to riluzole within 3 months of baseline, pregnancy, breast-feeding, inadequate contraception, WBC&lt;3800/mm3, creatinine&gt;2 mg/dL, ALT&gt;2xULN, unstable medical or psychiatric condition, and any of the following medication within 4 weeks of baseline: investigational drug, glutamatergic drugs, cytochrome P450 1A2 inhibitors, anticonvulsants, potentially hepatotoxic medications. Antidepressants or neuroleptics in unstable dosage for 4 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral riluzole 100 or 200 mg/day (18 and 23 patients in each arm, respectively) ; placebo (matching placebo; 22 patients). No titration.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-26 14:50:33 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: change in maximal chorea (UHDRS).<BR/>Secondary:</P>
<UL>
<LI>TMS (UHDRS).</LI>
<LI>Total dystonia score (UHDRS).</LI>
<LI>Stroop Interference Test (UHDRS).</LI>
<LI>Independence Scale (UHDRS).</LI>
<LI>Safety and tolerability (proportion of patients not completing the study, occurrence and severity of adverse events, number of treatment suspensions or withdrawals, changes in blood pressure and laboratory test abnormalities.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Reduction in chorea at 8 weeks for an efficacious dosage of 200 mg/d: -0.2 ±2.9 points (100 mg), -2.2±3.3 points (200 mg) and 0.7±3.4 points (placebo). Excess of hepatoxicity with efficacious dosage.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 14:51:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Roos-RA">
<CHAR_METHODS MODIFIED="2009-04-10 21:01:42 +0100" MODIFIED_BY="[Empty name]">
<P>4-week double-blind, cross-over study. No washout period. Method of randomisation: not described.<BR/>Results presented as combined data from treatment and placebo periods.<BR/>Intention-to-treat data analysis.<BR/>Location: 1 centre (Belgium).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-10 21:01:51 +0100" MODIFIED_BY="[Empty name]">
<P>22 patients with no drop-outs. 9 male and 13 female patients.<BR/>Mean age of participants: 49 years.<BR/>Mean disease duration: not described.<BR/>Inclusion criteria: clinical and genetically proven HD, &lt;70 years of age, normal liver and kidney function.<BR/>Exclusion criteria: systemic diseases and other disorders of central nervous system.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-10 21:02:12 +0100" MODIFIED_BY="[Empty name]">
<P>Oral Tiapride 300 mg/day, no titration.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-26 14:51:36 +0100" MODIFIED_BY="[Empty name]">
<P>Total number of choreic movements during 2 minutes (video and doppler-radar recording).<BR/>Self-assessment analogue 3-point scale for patient and a 5-point scale for family.<BR/>Side-effects (quantification of a parkinsonian effect - motor performance speed) and questionnaire for patient about AE.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Negative for efficacy measures. No carry-over effect documented.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 14:53:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stocchi-F">
<CHAR_METHODS MODIFIED="2009-04-10 21:02:48 +0100" MODIFIED_BY="[Empty name]">
<P>4-week open trial followed by 4-week double-blind, parallel study. Method of randomisation: not described.<BR/>Results presented for each arm of the study.<BR/>Intention-to-treat data analysis.<BR/>Location: 1 centre (Italy).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-10 21:02:53 +0100" MODIFIED_BY="[Empty name]">
<P>10 patients with 0 drop-outs. 5 male and 5 female patients.<BR/>Mean age of participants: 52.2±13.9 years.<BR/>Mean disease duration: 3.8±1.1 years.<BR/>Inclusion criteria: clinical signs and positive family history of HD.<BR/>Exclusion criteria: not described.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral Transdihydrolisuride 5 mg/day and placebo. No titration.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-10 21:08:04 +0100" MODIFIED_BY="[Empty name]">
<P>Disease severity (Marsden-Quinn Rating Scale).<BR/>AIMS.<BR/>MMSE.<BR/>Rapid wrist movements (neurophysiological recording).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-26 14:53:34 +0100" MODIFIED_BY="[Empty name]">
<P>Results given to the full extension of the trial.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 14:54:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-TETRA_x002d_HD">
<CHAR_METHODS MODIFIED="2009-04-10 21:03:13 +0100" MODIFIED_BY="[Empty name]">
<P>13-week double-blind (follow-up:1 week), unbalanced (treatment:placebo - 2:1) parallel study. Method of randomisation: computer generated.<BR/>Results presented for each arm of the study.<BR/>Intention-to-treat data analysis.<BR/>Location: 16 centres (USA).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-26 14:54:14 +0100" MODIFIED_BY="[Empty name]">
<P>84 patients, 6 drop-outs. 32 male and 52 female patients.<BR/>Mean age of participants: 49.2±9.1 years.<BR/>Mean disease duration: 8.3±4.6 years.<BR/>Inclusion criteria: chorea, family history, CAG&#8805;37. Ambulatory independent, TFC-UHDRS&gt;5, chorea-UHDRS&#8805;5. Presence of caregiver.<BR/>Exclusion criteria: disabling depression, dysphagia or dysarthria, treatment with TBZ or with dopamine-depleting drug, monoamine oxidase inhibitors, levodopa, dopamine agonist, amantadine or memantine. Off dopamine D2 blockers for &lt;4 weeks, unstable dosage of benzodiazepines or antidepressant in previous 8 weeks.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-10 21:04:15 +0100" MODIFIED_BY="[Empty name]">
<P>Oral tetrabenazine 100 mg/day (maximum dose for titration) (30 patients) and placebo (identical in appearance, 54 patients). (mean dosage=not available).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-10 21:07:09 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: change in total maximal chorea (UHDRS).<BR/>Secondary:</P>
<UL>
<LI>Change in CGI (UHDRS).</LI>
<LI>Change in total motor score (UHDRS).</LI>
<LI>Gait score (UHDRS).</LI>
<LI>Functional checklist (UHDRS).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-10 21:07:47 +0100" MODIFIED_BY="[Empty name]">
<P>Change in chorea grade (-5.0±0.5 tetrabenazine vs -1.5±0.7 placebo; p=0.0001).<BR/>Change in CGI (3.0±0.2 tetrabenazine vs 3.7±0.2 placebo; p=0.007).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 14:56:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-TREND_x002d_HD">
<CHAR_METHODS MODIFIED="2009-04-10 21:09:05 +0100" MODIFIED_BY="[Empty name]">
<P>32-week double-blind, placebo controlled, parallel study. Method of randomisation: computer generated blocking.<BR/>Results presented presented for each arm of the study.</P>
<P>Modified intention-to-treat data analysis (randomised and at least one post-baseline efficacy assessment).<BR/>Location: 41 centres (USA and Canada).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-26 14:56:18 +0100" MODIFIED_BY="[Empty name]">
<P>316 patients.<BR/>Inclusion Criteria: &gt;35 years, clinical HD and confirmatory family history of HD, and/or genetic diagnosis. Ambulatory, not requiring skilled nursing care (TFC-UHDRS&gt;7), chorea score (UHDRS)&gt;2 in one extremity. Maximal dystonia &#8804;2 and maximal bradykinesia &#8804;2 Stable dosages of non-competitive NMDA receptor antagonists, and/or antiepileptic medications for 60 days prior to baseline. Females of child-bearing potential must use adequate birth control.<BR/>Exclusion Criteria: History of established diagnosis of tardive dyskinesia, clinical evidence of unstable medical or psychiatric illness, clinically significant active and unstable psychotic disease (hallucinations or delusions). Major depression (Beck Depression Inventory [BDI]-II Score&gt;20) at Screening Visit. Suicidal ideation (BDI-II item 9&#8805;2) at Screening Visit. History of clinically significant substance abuse within 12 months of Baseline Visit. Pregnant/lactating women. Participation in other drug studies within 60 days prior to Baseline Visit. Previous participation in any investigational study of ethyl-EPA (Miraxion&#8482;) .Use of aspirin at daily dosage greater than 325 mg/day. Exclusionary Drugs (within 6 months Baseline Visit): Depot neuroleptics. Exclusionary Drugs (within 60 days Baseline Visit): Omega-3 supplementation, tetrabenazine or reserpine, high dose and/or variable dose oral anti-psychotic medications, steroid (other than topical), selenium supplements&gt;55 mcg/day, lithium, benzodiazepines (except for low dose), anticoagulants.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Oral ethyl-EPA 2 g/day (158 patients) and placebo (158 patients). No titration .</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-10 20:53:26 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: effect on TMS-4 (UHDRS) at 6 months.<BR/>Secondary:</P>
<UL>
<LI>Chorea (UHDRS).</LI>
<LI>TMS (UHDRS).</LI>
<LI>Clinical Global Impression (CGI-UHDRS).</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-10 21:07:39 +0100" MODIFIED_BY="[Empty name]">
<P>Results given to the all extension of the trial. The results from a 6-month open label extension phase are expected.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 14:56:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vaddadi-K">
<CHAR_METHODS MODIFIED="2009-04-10 21:10:48 +0100" MODIFIED_BY="[Empty name]">
<P>2-year double-blind, parallel study. Method of randomisation: not described.<BR/>Results presented for each arm of the study.<BR/>Per-protocol data analysis.<BR/>Location: 1 centre (Australia).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-26 14:56:24 +0100" MODIFIED_BY="[Empty name]">
<P>19 patients, 2 drop-outs. 8 male and 9 female patients (per-protocol cohort).<BR/>Mean age of participants: 49.8 ± 8.5 years (per-protocol cohort).<BR/>Inclusion criteria: genetically established HD.<BR/>Exclusion criteria: any other neurological illness or injury, poorly controlled epilepsy, end-stage HD (dementia, spasticity, continuous care needed), insulin-dependent diabetic, major psychiatric disorder without stable antidepressant or antipsychotic medication for &#8804; 6 months, high dose of antioxidants (vit. E).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-26 14:56:41 +0100" MODIFIED_BY="[Empty name]">
<P>Oral unsaturated fatty acids (acids linoleic, gamma-linolenic, dihomo-gammalinolenic, ethyl-eicosapentaenoic acid, docosahexaenoic acid, alpha-lipoic acid) 8 g/day (9 patients) and placebo (identical appearing capsule containing hydrogenated coconut oil and anti-oxidants as in active treatment) in 8 patients.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-10 21:10:53 +0100" MODIFIED_BY="[Empty name]">
<P>Change in dyskinesia (Rockland-Simpson Dyskinesia Rating Scale).<BR/>Change in UHDRS items: motor, functional, behavioural and cognitive.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Anti-dyskinetic effect: 7.0±3.7 (placebo) vs -4.3±2.1 (active), p=0.01. Results from an average follow-up of 19 and 20 months for treatment and placebo, respectively.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 15:03:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-van-Vugt-J">
<CHAR_METHODS>
<P>4-week double-blind, parallel study. Method of randomisation: not described.<BR/>Results presented for each arm of the study, after grouping for neuroleptic previous use. <BR/>Per-protocol data analysis.<BR/>Location: 1 centre (The Netherlands).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-10 21:11:07 +0100" MODIFIED_BY="[Empty name]">
<P>33 patients, 7 drop-outs. 15 male and 18 female patients.<BR/>Mean age of participants: 48.4±10.8 years.<BR/>Mean disease duration: 9.4±5.9 years.<BR/>Inclusion criteria: clinically and genetically established HD with typical choreatic movements.<BR/>Exclusion criteria: demented/psychotic or history of clozapine use.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-10 21:11:43 +0100" MODIFIED_BY="[Empty name]">
<P>Oral clozapine 150 mg/day (maximum dosage). Titration: 25 mg each day during the first week. (mean dosage=not available).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-26 15:03:17 +0100" MODIFIED_BY="[Empty name]">
<P>1. Change in chorea grade (AIMS, UHDRS chorea).<BR/>2. Voluntary motor performance (UHDRS motor).<BR/>3. Functional capacity (modified PD self-reported disability scale).<BR/>4. Semi-quantitative patient questionnaire.<BR/>5. Partner evaluated disability questionnaire.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-10 21:11:19 +0100" MODIFIED_BY="[Empty name]">
<P>Negative for efficacy measures.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-04-26 15:05:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Verhagen-Metman-L">
<CHAR_METHODS MODIFIED="2009-04-26 15:04:26 +0100" MODIFIED_BY="[Empty name]">
<P>4-week double-blind, cross-over study. No washout period. Method of randomisation: random number tables with blocking,<BR/>Results presented as combined data from treatment and placebo periods.<BR/>Per-protocol data analysis.<BR/>Location: 1 centre (USA)<BR/>Note: the authors explain the non-inclusion of a washout period by the relative short half-life of amantadine (12 hours in young adults) and the extrapolation of the clinical observation that a carry-over of the antidyskinetic effect of amantadine in Parkinson's disease is limited to 2 to 3 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>24 patients, 2 drop-outs. 16 male and 8 female patients.<BR/>Median age of participants: 52 years (range: 32-68 years).<BR/>Median disease duration: 6 years (range: 2-15 years).<BR/>Inclusion criteria: HD confirmed by genetic testing or family history, ratable chorea, ambulatory, ability of complying and reporting compliance and adverse events.<BR/>Exclusion criteria: renal impairment (elevated plasma creatinine), MMSE&lt;18/30, past history of psychosis, concomitant conventional neuroleptic use (not on a steady low-dose).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-10 21:12:26 +0100" MODIFIED_BY="[Empty name]">
<P>Oral amantadine 100-400 mg/day; titration within 4 days (mean dosage: 386 mg/d).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-26 15:05:22 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: chorea severity (UHDRS-28-point scale) at rest and at its maximum - by videotape.</P>
<P>
<BR/>Secondary:</P>
<UL>
<LI>Change in maximal and at rest chorea (UHDRS) - live.</LI>
<LI>Parkinson score (motor UHDRS; items 6,7,9, 10) - live.</LI>
<LI>Plasma amantadine levels.</LI>
<LI>Cognitive test battery (MMSE, Repeated Battery for the Assessment of Neurological Syndromes, Verbal Fluency Test, Symbol Digit Modalities Test, Stroop Interference Test).</LI>
<LI>Safety and tolerability.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-26 15:05:35 +0100" MODIFIED_BY="[Empty name]">
<P>Reduction for maximal median chorea (18% vs 5%, p=0.0007).<BR/>Reduction for rest median chorea (25% vs 5%, p=0.013).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>AE - Adverse events.<BR/>AIMS - Abnormal Involuntary Movement Scale.<BR/>ALT -  Alanine aminotransferase.<BR/>ANA - Anti-nuclear antibody.<BR/>CAG - Glutamine.</P>
<P>CGI - Clinical Global Impression.<BR/>CNS - Central Nervous system.</P>
<P>EKG - Electrocardiogram.<BR/>EPA - Eicosapentaenoic acid.<BR/>HD - Huntington's disease.<BR/>HDFCS - Huntington Disease Functional Capacity.<BR/>HDMRS - Huntington Disease Rating Motor Scale.</P>
<P>Hx - History.</P>
<P>L-DOPA - Levo-3,4-dihydroxy-L-phenylalanine.<BR/>MMSE - Mini-Mental State Examination.<BR/>NMDA - M-methyl-D-asparte.<BR/>OPC - Oligomeric Proanthocyanidins.<BR/>SLC-90R - Symptom Checklist-90-R.<BR/>TBZ - Tetrabenazine.<BR/>TFC - Total Functioning Capacity.<BR/>TMS - Total Motor Score.<BR/>UHDRS - Unified Huntington Disease Revised Scale.</P>
<P>ULN - Upper-limit normal.</P>
<P>vs- versus.<BR/>WBC - White blood count.<BR/>80H2&#8217;dG - 8-Hydroxy-2'-deoxyguanosine.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-04-26 15:08:36 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Albanese-A">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Albano-C">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-18 16:48:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Alpay-M">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-18 16:48:51 +0000" MODIFIED_BY="[Empty name]">
<P>case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Aminoff-MJ">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Asher-SW">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Barr-AN">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bassi-S-_x0028_a_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bonelli-RM">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bonuccelli-U">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Braun-A">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Caine-ED">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Caparros_x002d_Lefebvre-D">
<CHAR_REASON_FOR_EXCLUSION>
<P>case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Caraceni-TA-_x0028_a_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Caraceni-TA-_x0028_b_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Caraceni-TA-_x0028_c_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Carman-JS">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Corsini-GU">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dalby-M">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dallochio-C">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-de-Tommaso-_x0028_a_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-18 16:51:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Tommaso-_x0028_b_x0029_">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-18 16:51:50 +0000" MODIFIED_BY="[Empty name]">
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-de-Tommaso-_x0028_c_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dest_x00e9_e-A">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dupont-E">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fernandez-HH">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fisher--R-_x0028_a_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fisher-R-_x0028_b_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Fog-R">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Foster-NL">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-04-26 15:07:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frattola-L-_x0028_a_x0029_">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-04-26 15:07:44 +0100" MODIFIED_BY="[Empty name]">
<P>Jadad score&lt;3</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-18 16:51:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Frattola-L-_x0028_b_x0029_">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-18 16:51:39 +0000" MODIFIED_BY="[Empty name]">
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gim_x00e9_nez_x002d_Rold_x00e1_n-S">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Girke-W">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Girotti-F">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Giuffra-ME">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gray-MW">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Haslam-MT">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Heckman-JM">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jankovic-J">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kartzinel-R">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leng-TR">
<CHAR_REASON_FOR_EXCLUSION>
<P>no blinding</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Leonard-DP">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lucetti-C_x0028_a_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>open label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lucetti-C_x0028_b_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Manyam-BV">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mattson-B">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-McLellan-D">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nutt-JG-_x0028_a_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nutt-JG-_x0028_b_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Ondo-WG">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pakkenberg-H">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Paleacu-D">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-18 16:50:33 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pearce-I">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-18 16:50:33 +0000" MODIFIED_BY="[Empty name]">
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Perry-TL-_x0028_a_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Perry-TL-_x0028_b_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-12 21:58:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Perry-TL-_x0028_c_x0029_">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-12 21:58:18 +0000" MODIFIED_BY="[Empty name]">
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Piccinin-G">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-18 16:49:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saft-C-_x0028_a_x0029_">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-18 16:49:06 +0000" MODIFIED_BY="[Empty name]">
<P>case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saft-C-_x0028_b_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scigliano-G">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Scotti-G">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Seppi-K">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shoulson-I_x0028_a_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shoulson-I_x0028_b_x0029_">
<CHAR_REASON_FOR_EXCLUSION>
<P>not randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Shults-C">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Squittieri-F">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Swash-M">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-12 22:03:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Symington-GR">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-12 22:03:22 +0000" MODIFIED_BY="[Empty name]">
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tarsy-D">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tell-G">
<CHAR_REASON_FOR_EXCLUSION>
<P>not controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Terrence-CF">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tolosa-ES">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tourian-AY">
<CHAR_REASON_FOR_EXCLUSION>
<P>outcome meaures not clinical <BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-18 16:49:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Van-Duijn-E">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-18 16:49:11 +0000" MODIFIED_BY="[Empty name]">
<P>case series</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Vestergaard-P">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-18 16:49:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Vitale-P">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-18 16:49:15 +0000" MODIFIED_BY="[Empty name]">
<P>n&lt;10</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Walker-FO">
<CHAR_REASON_FOR_EXCLUSION>
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Worrall-EP">
<CHAR_REASON_FOR_EXCLUSION>
<P>n&lt;10<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-18 16:49:40 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zesiewicz-T">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-18 16:49:40 +0000" MODIFIED_BY="[Empty name]">
<P>open-label study</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-11-18 16:50:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zinzi-P">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-11-18 16:50:12 +0000" MODIFIED_BY="[Empty name]">
<P>not controlled</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>Swash M - two studies published in the same article: 1) non-controlled with tetrabenazine and 2) tetrabenazine vs amantadine. Only two Huntington´s disease patients were included.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-04-26 15:12:14 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2009-04-26 15:08:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Curtis-A">
<CHAR_METHODS MODIFIED="2009-04-26 15:08:46 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, cross-over study. Washout periods: 5 weeks in-between blocks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-10 21:15:59 +0100" MODIFIED_BY="[Empty name]">
<P>44 patients with HD.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-10 21:16:00 +0100" MODIFIED_BY="[Empty name]">
<P>Oral nabilone, 1-2 mg/day during 15-week.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-11 22:51:16 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: change in TMS-UHDRS.<BR/>Secondary: change in behaviour and cognitive scales (UHDRS), change in SF-36 scale, neuropsychiatric Inventory.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-10 21:16:38 +0100" MODIFIED_BY="[Empty name]">
<P>Data as in http://clinicaltrials.gov.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2009-04-26 15:09:18 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-DIMOND_x002d_A">
<CHAR_METHODS MODIFIED="2009-04-26 15:09:02 +0100" MODIFIED_BY="[Empty name]">
<P>Non-randomised, open label, uncontrolled, single group assignment, safety study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-26 15:09:18 +0100" MODIFIED_BY="[Empty name]">
<P>Clinical features of HD and confirmatory family history of HD or a CAG repeat expansion&#8805; 36, Stage I,II,III HD and a TFC-UHDRS&#8805;5.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-10 21:16:07 +0100" MODIFIED_BY="[Empty name]">
<P>Dimebon 30 or 60 mg/day for 7 days.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-11 22:59:44 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: Dose-limiting toxicity.<BR/>Secondary: UHDRS.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-10 21:16:19 +0100" MODIFIED_BY="[Empty name]">
<P>Data as in http://clinicaltrials.gov.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2009-04-26 15:12:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-PHEND_x002d_HD">
<CHAR_METHODS MODIFIED="2009-04-26 15:09:05 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, in parallel safety study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-26 15:09:49 +0100" MODIFIED_BY="[Empty name]">
<P>Subjects with clinical diagnosis of HD and family history of HD or a CAG repeat expansion&#8805;37, TFC-UHDRS&#8805;7, Stages I, II HD and TFC &#8805;7.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-10 21:16:24 +0100" MODIFIED_BY="[Empty name]">
<P>Sodium phenylbutyrate 15g/day vs. placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-11 22:58:26 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: proportion of subjects able to complete treatment.</P>
<P>Secondary: various parameters of safety, tolerability, motor, cognitive and functional (UHDRS), biochemical and genetic measures.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-04-26 15:12:14 +0100" MODIFIED_BY="[Empty name]">
<P>Data as in http://clinicaltrials.gov.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2009-04-26 15:19:49 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR MODIFIED="2009-04-26 15:19:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Atomoxetine">
<CHAR_STUDY_NAME MODIFIED="2009-04-26 15:10:08 +0100" MODIFIED_BY="[Empty name]">
<P>Atomoxetine for Attention Deficits in Adults With Mild HD: A Randomised, Placebo-Controlled Crossover Study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-04-26 15:12:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind (Subject, Caregiver, Investigator, Outcomes Assessor), cross-over design, safety/efficacy study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-11 22:48:58 +0100" MODIFIED_BY="[Empty name]">
<P>Confirmed Huntington's disease diagnosis, mild HD, complaints of poor attention.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-11 22:48:58 +0100" MODIFIED_BY="[Empty name]">
<P>Atomoxetine 40 mg/day vs. placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-26 15:18:20 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: CAARS score and cognitive summary score</P>
<P>Secondary: individual cognitive tests, UHDRS motor score, SCL-90-R global index score.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-04-26 15:10:55 +0100" MODIFIED_BY="[Empty name]">
<P>November 2005.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-04-26 15:19:30 +0100" MODIFIED_BY="[Empty name]">
<P>Leigh Beglinger, Ph.D., University of Iowa.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-04-11 22:48:58 +0100" MODIFIED_BY="[Empty name]">
<P>Data as in http://clinicaltrials.gov.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-04-26 15:15:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-CIT_x002d_HD">
<CHAR_STUDY_NAME MODIFIED="2009-04-26 15:12:48 +0100" MODIFIED_BY="[Empty name]">
<P>A randomised, placebo-controlled pilot study in Huntington's Disease (CIT-HD).</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-04-26 15:13:14 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled, parallel design, efficacy study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-08-25 12:38:16 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis of HD (confirmatory genetic testing, presence of unequivocal motor signs of HD (e.g., chorea) in combination with a positive family history.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-04-26 15:14:40 +0100" MODIFIED_BY="[Empty name]">
<P>Citalopram 20mg/day vs. placebo during 16 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-26 15:14:48 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: effect on executive function.<BR/>Secondary: relation between executive function and functional status, effect on functional measures (health-related quality of life, work productivity, and self-reported attention), motor performance, and psychiatric status, effect on volumetrics and metabolics (i.e., N-Acetyl-Aspartate concentration) of neostriatum.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2009-04-11 22:52:17 +0100" MODIFIED_BY="[Empty name]">
<P>November 2005.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-04-26 15:15:38 +0100" MODIFIED_BY="[Empty name]">
<P>William H Adams: phone: 1-319-353-4411)/ e-mail: William-H-Adams@uiowa.edu.<BR/>Nicole R Ramza: phone:319-384-9408 / e-mail: Nicole-Ramza@uiowa.edu.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-04-26 15:15:24 +0100" MODIFIED_BY="[Empty name]">
<P>Data as in http://clinicaltrials.gov.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-04-26 15:19:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Memantine">
<CHAR_STUDY_NAME MODIFIED="2009-04-10 21:17:03 +0100" MODIFIED_BY="[Empty name]">
<P>A pilot study of Memantine for cognitive and behavioral dysfunction in Huntington's disease.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2009-04-26 15:15:46 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind (Subject, Caregiver, Investigator, Outcomes Assessor), cross-over design, safety/efficacy study.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-04-10 21:17:06 +0100" MODIFIED_BY="[Empty name]">
<P>Diagnosis of HD with current complaints of memory or concentration difficulties.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-08-25 13:52:05 +0100" MODIFIED_BY="[Empty name]">
<P>First 3 months, memantine 20 mg/day vs. placebo. Last 3 months, open label.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-04-26 15:16:03 +0100" MODIFIED_BY="[Empty name]">
<P>Primary: sensitive neuropsychological battery.</P>
<P>Secondary: behavioral and functional measures at 3 and 6months of treatment.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION MODIFIED="2009-04-26 15:19:49 +0100" MODIFIED_BY="[Empty name]">
<P>Jody Corey-Bloom, MD, PhD: phone: 858-642-3470 / e-mail: jcoreybl@vapop.ucsd.edu.</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES MODIFIED="2009-04-10 21:17:11 +0100" MODIFIED_BY="[Empty name]">
<P>Data as in http://clinicaltrials.gov.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>ADHD - Attention Deficit/Hyperactivity Disorder.<BR/>CAG - Glutamine.</P>
<P>CAARS - Conner's Adult ADHD Rating Scales.</P>
<P>HD -Huntington's disease.<BR/>SCL-90-R - Symptom Checklist-90-R.<BR/>TFC - Total Functioning Capacity.<BR/>UHDRS -Unified Huntington Disease Revised Scale.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2008-11-08 06:09:41 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2008-11-08 06:09:41 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Como-PG">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Consroe-P">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2008-11-08 06:09:41 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Cubo-E">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-De-Roover--J">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Goetz-CG">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hersch-G">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-INTRO_x002d_HD">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kieburtz-K">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-MINO">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Mateo-D">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Miraxion_x002d_Europe">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Murman-DL">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-O_x0027_Suilleabhain-P">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Quinn-N">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-RID_x002d_HD">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Roos-RA">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Stocchi-F">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-TETRA_x002d_HD">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-TREND_x002d_HD">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Vaddadi-K">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Verhagen-Metman-L">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-van-Vugt-J">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2009-04-26 15:21:37 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2009-04-26 15:21:37 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-11-08 03:39:23 +0000" MODIFIED_BY="[Empty name]">Unified Huntington's Disease Rating Scale (UHDRS)</TITLE>
<TABLE COLS="2" ROWS="6">
<TR>
<TD>
<P>
<B>COMPONENTS</B>
</P>
</TD>
<TD>
<P>
<B>items evaluated</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Motor Assessment<BR/>
</P>
</TD>
<TD>
<P>oculomotor function, dysarthria, chorea, dystonia, gait, postural stability.</P>
</TD>
</TR>
<TR>
<TD>
<P>Cognitive Assessment<BR/>
</P>
</TD>
<TD>
<P>phonetic verbal fluency test, Symbol Digit Modalities Test, the Stroop Test.</P>
</TD>
</TR>
<TR>
<TD>
<P>Behavioral Assessment<BR/>
</P>
</TD>
<TD>
<P>affect, thought content, coping styles.</P>
</TD>
</TR>
<TR>
<TD>
<P>Functional Assessment<BR/>
</P>
</TD>
<TD>
<P>Independence Scale, (checklist of common daily tasks) Total Functional Capacity (TFC).</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2">
<P>
<LINK REF="REF-HSG-1996" TYPE="REFERENCE">HSG 1996</LINK>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2008-08-25 13:44:25 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2008-08-25 13:44:25 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Amantadine</NAME>
<CONT_OUTCOME CHI2="2.7084454780841334" CI_END="0.43171128767724515" CI_START="-0.9255728454021372" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.24693077886244602" ESTIMABLE="YES" I2="63.07845189826868" I2_Q="0.0" ID="CMP-001.01" MODIFIED="2008-08-25 13:44:25 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.09981828700530604" P_Q="1.0" P_Z="0.47575126680405777" Q="0.0" RANDOM="YES" SCALE="3.535294108866889" SORT_BY="EFFECT_SIZE" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.1513735951890038" TOTALS="YES" TOTAL_1="46" TOTAL_2="47" UNITS="" WEIGHT="100.0" Z="0.7131527164423321">
<NAME>Change in maximal chorea (%)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0023242224318892335" CI_START="-1.208740218961172" EFFECT_SIZE="-0.6032079982646414" ESTIMABLE="YES" MEAN_1="-11.43" MEAN_2="-1.79" ORDER="2" SD_1="16.54" SD_2="14.8" SE="0.3089506876008394" STUDY_ID="STD-Verhagen-Metman-L" TOTAL_1="22" TOTAL_2="22" WEIGHT="48.57331781454447"/>
<CONT_DATA CI_END="0.6499903307526292" CI_START="-0.47083290795307386" EFFECT_SIZE="0.08957871139977772" ESTIMABLE="YES" MEAN_1="0.0" MEAN_2="-1.25" ORDER="1" SD_1="14.33" SD_2="13.13" SE="0.28592954961076167" STUDY_ID="STD-O_x0027_Suilleabhain-P" TOTAL_1="24" TOTAL_2="25" WEIGHT="51.42668218545553"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-04-10 21:19:10 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Figure 1_sintomatico.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2008-12-04 04:12:39 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA2AAAAL7CAIAAAAUJnHHAACAAElEQVR42uy9d3wWxfq4bUIXQpeO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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-04-10 21:19:10 +0100" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: Amantadine. Change in maximal chorea (%) [extrapolated SD (r=0.5)].</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA0EAAACQCAMAAAD5qZD8AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>